Form 10-Q

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

0001193125-18-157513.txt : 20180509 0001193125-18-157513.hdr.sgml : 20180509 20180509160655 ACCESSION NUMBER: 0001193125-18-157513 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 58 CONFORMED PERIOD OF REPORT: 20180331 FILED AS OF DATE: 20180509 DATE AS OF CHANGE: 20180509 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CATALYST PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001369568 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-33057 FILM NUMBER: 18818285 BUSINESS ADDRESS: STREET 1: 355 ALHAMBRA CIRCLE STREET 2: SUITE 1250 CITY: CORAL GABLES STATE: FL ZIP: 33134 BUSINESS PHONE: (305) 529-2522 MAIL ADDRESS: STREET 1: 355 ALHAMBRA CIRCLE STREET 2: SUITE 1250 CITY: CORAL GABLES STATE: FL ZIP: 33134 FORMER COMPANY: FORMER CONFORMED NAME: CATALYST PHARMACEUTICAL PARTNERS, INC. DATE OF NAME CHANGE: 20110215 FORMER COMPANY: FORMER CONFORMED NAME: Catalyst Pharmaceutical Partners, Inc. DATE OF NAME CHANGE: 20060719 10-Q 1 d556138d10q.htm FORM 10-Q Form 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

[Mark One]

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended March 31, 2018

☐	TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File No. 001-33057

CATALYST PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)


Delaware		76-0837053
(State or other jurisdiction of incorporation or organization)		(IRS Employer Identification No.)

355 Alhambra Circle Suite 1250 Coral Gables, Florida		33134
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (305) 420-3200

Indicate by checkmark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such report(s), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of “accelerated filer”, “large accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act (Check one):

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date 102,596,164 shares of common stock, $0.001 par value per share, were outstanding as of May 4, 2018.

CATALYST PHARMACEUTICALS, INC.

INDEX

PART I. FINANCIAL INFORMATION


Item 1.	FINANCIAL STATEMENTS

	Consolidated balance sheets at March 31, 2018 (unaudited) and December 31, 2017	3

	Consolidated statements of operations and comprehensive loss for the three months ended March 31, 2018 and 2017 (unaudited)	4

	Consolidated statement of stockholders’ equity for the three months ended March 31, 2018 (unaudited)	5

	Consolidated statements of cash flows for the three months ended March 31, 2018 and 2017 (unaudited)	6

	Notes to unaudited consolidated financial statements	7

Item 2.	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	17

Item 3.	QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISK	29

Item 4.	CONTROLS AND PROCEDURES	29

	PART II. OTHER INFORMATION

Item 1.	LEGAL PROCEEDINGS	30

Item 1A.	RISK FACTORS	30

Item 2.	UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS	30

Item 3.	DEFAULTS UPON SENIOR SECURITIES	30

Item 4.	MINE SAFETY DISCLOSURE	30

Item 5.	OTHER INFORMATION	30

Item 6.	EXHIBITS	30

SIGNATURES		32

CATALYST PHARMACEUTICALS, INC.

CONSOLIDATED BALANCE SHEETS


	March 31, 2018			December 31, 2017
	(unaudited)
ASSETS
Current Assets:
Cash and cash equivalents	$	19,600,591		$	57,496,702
Short-term investments		58,342,578			26,516,711
Prepaid expenses and other current assets		992,828			1,173,744

Total current assets		78,935,997			85,187,157
Property and equipment, net		183,370			191,385
Deposits		8,888			8,888

Total assets	$	79,128,255		$	85,387,430

LIABILITIES AND STOCKHOLDERS’ EQUITY

Current Liabilities:
Accounts payable	$	805,023		$	1,945,575
Accrued expenses and other liabilities		1,926,371			2,320,587

Total current liabilities		2,731,394			4,266,162

Accrued expenses and other liabilities, non-current		150,395			157,456

Total liabilities		2,881,789			4,423,618

Commitments and contingencies

Stockholders’ equity:
Preferred stock, $0.001 par value, 5,000,000 shares authorized: none issued and outstanding at March 31, 2018 and December 31, 2017		—			—
Common stock, $0.001 par value, 150,000,000 shares authorized; 102,586,164 shares and 102,549,498 shares issued and outstanding at March 31, 2018 and December 31, 2017, respectively		102,586			102,549
Additional paid-in capital		208,426,045			207,421,710
Accumulated deficit		(132,260,339	)		(126,560,447	)
Accumulated other comprehensive loss		(21,826	)		—

Total stockholders’ equity		76,246,466			80,963,812

Total liabilities and stockholders’ equity	$	79,128,255		$	85,387,430

The accompanying notes are an integral part of these consolidated financial statements.

CATALYST PHARMACEUTICALS, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (unaudited)


	For the Three Months Ended March 31,
	2018			2017
Operating costs and expenses:
Research and development	$	3,259,042		$	2,813,929
General and administrative		2,674,398			1,865,942

Total operating costs and expenses		5,933,440			4,679,871

Loss from operations		(5,933,440	)		(4,679,871	)
Other income, net		233,548			109,977
Change in fair value of warrants liability		—			(397,235	)

Loss before income taxes		(5,699,892	)		(4,967,129	)
Provision for income taxes		—			—

Net loss	$	(5,699,892	)	$	(4,967,129	)

Net loss per share – basic and diluted	$	(0.06	)	$	(0.06	)

Weighted average shares outstanding – basic and diluted		102,557,350			82,972,316

Other comprehensive loss:
Unrealized gain (loss) on available-for-sale securities		(21,826	)		—

Comprehensive loss	$	(5,721,718	)	$	(4,967,129	)

The accompanying notes are an integral part of these consolidated financial statements.

CATALYST PHARMACEUTICALS, INC.

CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY (unaudited)

For the three months ended March 31, 2018


	Preferred Stock		Common Stock		Additional Paid-in Capital		Accumulated Deficit			Accumulated Other Comprehensive Loss			Total
Balance at December 31, 2017	$	—	$	102,549	$	207,421,710	$	(126,560,447	)	$	—		$	80,963,812
Issuance of stock options for services		—		—		971,340		—			—			971,340
Exercise of stock options for common stock		—		37		32,995		—			—			33,032
Other comprehensive loss		—		—		—		—			(21,826	)		(21,826	)
Net loss		—		—		—		(5,699,892	)		—			(5,699,892	)

Balance at March 31, 2018	$	—	$	102,586	$	208,426,045	$	(132,260,339	)	$	(21,826	)	$	76,246,466

The accompanying notes are an integral part of these consolidated financial statements.

CATALYST PHARMACEUTICALS, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)


	For the Three Months Ended March 31,
	2018			2017
Operating Activities:
Net loss	$	(5,699,892	)	$	(4,967,129	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation		8,015			12,958
Stock-based compensation		971,340			754,144
Change in fair value of warrants liability		—			397,235
(Increase) decrease in:
Prepaid expenses and other current assets and deposits		180,916			118,082
Increase (decrease) in:
Accounts payable		(1,140,552	)		(15,248	)
Accrued expenses and other liabilities		(401,277	)		(178,917	)

Net cash used in operating activities		(6,081,450	)		(3,878,875	)

Investing Activities:
Purchase of investments		(31,847,693	)		(33,145	)

Net cash provided by (used in) investing activities		(31,847,693	)		(33,145	)

Financing Activities:
Proceeds from exercise of stock options		33,032			—

Net cash provided by (used in) financing activities		33,032			—

Net increase (decrease) in cash and cash equivalents		(37,896,111	)		(3,912,020	)
Cash and cash equivalents - beginning of period		57,496,702			13,893,064

Cash and cash equivalents - end of period	$	19,600,591		$	9,981,044

Non-cash investing activities:
Unrealized loss on available-for-sale securities	$	21,826		$	—

The accompanying notes are an integral part of these consolidated financial statements.

CATALYST PHARMACEUTICALS, INC.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

1.	Organization and Description of Business.

Catalyst Pharmaceuticals, Inc. (the Company) is a development-stage biopharmaceutical company focused on developing and commercializing innovating therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, including Lambert-Eaton Myasthenic Syndrome (LEMS), Congenital Myasthenic Syndromes (CMS), MuSK antibody positive myasthenia gravis, and infantile spasms.

Since inception, the Company has devoted substantially all of its efforts to business planning, research and development, recruiting management and technical staff, acquiring operating assets and raising capital. The Company’s primary focus is on the development and commercialization of its drug candidates. The Company has incurred operating losses in each period from inception through March 31, 2018. The Company has been able to fund its cash needs to date through several public and private offerings of its common stock and warrants, through government grants, and through an investment by a strategic purchaser. See Note 10.

Capital Resources

While there can be no assurance, based on currently available information, the Company estimates that it has sufficient resources to support its operations for at least the next 12 months.

The Company may raise additional funds in the future, if required for its business, through public or private equity offerings, debt financings, corporate collaborations, governmental research grants or other means. The Company may also seek to raise new capital to fund additional product development efforts, even if it has sufficient funds for its planned operations. Any sale by the Company of additional equity or convertible debt securities could result in dilution to the Company’s current stockholders. There can be no assurance that any required additional funding will be available to the Company at all or available on terms acceptable to the Company. Further, to the extent that the Company raises additional funds through collaborative arrangements, it may be necessary to relinquish some rights to the Company’s drug candidates or grant sublicenses on terms that are not favorable to the Company. If the Company is not able to secure additional funding when needed, the Company may have to delay, reduce the scope of, or eliminate one or more research and development programs, which could have an adverse effect on the Company’s business.

2.	Basis of Presentation and Significant Accounting Policies.

INTERIM FINANCIAL STATEMENTS. The accompanying unaudited interim consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP), and pursuant to the rules and regulations of the Securities and Exchange Commission (SEC) for reporting of interim financial information. Pursuant to such rules and regulations, certain information and note disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been omitted. The consolidated balance sheet as of December 31, 2017 included in this Form 10-Q was derived from the audited financial statements and does not include all disclosures required by U.S. GAAP.

In the opinion of management, the accompanying unaudited interim consolidated financial statements of the Company contain all adjustments (consisting of only normal recurring adjustments) necessary to present fairly the financial position of the Company as of the dates and for the periods presented. Accordingly, these consolidated statements should be read in conjunction with the financial statements and notes thereto for the year ended December 31, 2017 included in the 2017 Annual Report on Form 10-K filed by the Company with the SEC. The results of operations for the three months ended March 31, 2018 are not necessarily indicative of the results to be expected for any future period or for the full 2018 fiscal year.

2.	Basis of Presentation and Significant Accounting Policies (continued).

PRINCIPLES OF CONSOLIDATION. The consolidated financial statements include the Company’s accounts and those of its wholly-owned subsidiary Catalyst Pharmaceuticals Ireland, Ltd. (“Catalyst Ireland”). All intercompany accounts and transactions have been eliminated in consolidation. Catalyst Ireland was organized in 2017.

USE OF ESTIMATES. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.

CASH AND CASH EQUIVALENTS. The Company considers all highly liquid instruments purchased with an original maturity of three months or less to be cash equivalents. Cash equivalents consist mainly of money market funds. The Company has substantially all of its cash and cash equivalents deposited with one financial institution. These amounts at times may exceed federally insured limits.

SHORT-TERM INVESTMENTS. The Company invests in short-term high credit-quality funds in order to obtain higher yields on its cash available for investments. At March 31, 2018 short-term investments consisted of a short-term bond fund and U.S. Treasuries. At December 31, 2017 short-term investments consisted of a short-term bond fund. Such investments are not insured by the Federal Deposit Insurance Corporation.

Short-term bond fund

The short-term bond fund is classified in trading securities. Trading securities are recorded at fair value based on the closing market price of the security. For trading securities, the Company recognizes realized gains and losses and unrealized gains and losses to earnings. At March 31, 2018 and December 31, 2017, the only investment classified as trading securities was the short-term bond fund. Unrealized gain (loss) for the three months ended March 31, 2018 and 2017 for trading securities was ($58,861) and $29,430, respectively, and is included in other income, net in the accompanying consolidated statements of operations.

U.S. Treasuries

U.S. Treasuries are classified as available-for sale-securities. The Company classifies available-for-sale securities with stated maturities of greater than three months from the date of purchase as short-term investments. At March 31, 2018, all U.S. Treasuries were due within one year. The Company records available-for-sale securities at fair value with unrealized gains and losses reported in accumulated other comprehensive income (loss) in stockholders’ equity. Realized gain and losses are included in other income, net and are derived using the specific identification method for determining the cost of securities sold. Interest income is recognized when earned and is included in other income, net in the consolidated statement of operations. The Company recognizes a charge when the declines in the fair value below the amortized cost basis of our available-for-sale securities are judged to be other-than-temporary. The Company considers various factors in determining whether to recognize an other-than-temporary charge, including whether the Company intends to sell the security or whether it is more likely than not that the Company would be required to sell the security before recovery of the amortized cost basis. The Company has not recorded any other than temporary impairment charges on its available-for-sale securities.

PREPAID EXPENSES AND OTHER CURRENT ASSETS. Prepaid expenses and other current assets consist primarily of prepaid research fees, prepaid pre-commercialization expenses, prepaid insurance and prepaid subscription fees. Prepaid research fees consist of advances for the Company’s product development activities, including drug manufacturing, contracts for pre-clinical studies, clinical trials and studies, regulatory affairs and consulting. Such advances are recorded as expense as the related goods are received or the related services are performed.

2.	Basis of Presentation and Significant Accounting Policies (continued).

FAIR VALUE OF FINANCIAL INSTRUMENTS. The Company’s financial instruments consist of cash and cash equivalents, short-term investments, accounts payables, accrued expenses and other liabilities, and warrants liability. At March 31, 2018 and December 31, 2017, the fair value of these instruments approximated their carrying value.

FAIR VALUE MEASUREMENTS. Current Financial Accounting Standards Board (FASB) fair value guidance emphasizes that fair value is a market-based measurement, not an entity-specific measurement. Therefore, a fair value measurement should be determined based on the assumptions that market participants would use in pricing the asset or liability. As a basis for considering market participant assumptions in fair value measurements, current FASB guidance establishes a fair value hierarchy that distinguishes between market participant assumptions based on market data obtained from sources independent of the reporting entity (observable inputs that are classified within Levels 1 and 2 of the hierarchy) and the reporting entity’s own assumptions that it believes market participants would use in pricing assets or liabilities (unobservable inputs classified within Level 3 of the hierarchy).

Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. Level 2 inputs are inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs may include quoted prices for similar assets and liabilities in active markets, as well as inputs that are observable for the asset or liability (other than quoted prices), such as interest rates, foreign exchange rates, and yield curves that are observable at commonly quoted intervals. Level 3 inputs are unobservable inputs for the asset or liability, which are typically based on an entity’s own assumptions, as there is little, if any, related market activity. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and considers factors specific to the asset or liability.


	Fair Value Measurements at Reporting Date Using
	Balances as of March 31, 2018		Quoted Prices in Active Markets for Identical Assets/Liabilities (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Cash and cash equivalents:
Money market funds	$	19,343,497	$	19,343,497	$	—	$	—

Short-term investments:
Short-term bond fund	$	26,496,992	$	26,496,992	$	—	$	—

U.S. Treasuries	$	31,845,586	$	—	$	31,845,586	$	—


	Balances as of December 31, 2017		Quoted Prices in Active Markets for Identical Assets/Liabilities (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Cash and cash equivalents:
Money market funds	$	56,820,688	$	56,820,688	$	—	$	—

Short-term investments:
Short-term bond fund	$	26,516,711	$	26,516,711	$	—	$	—

2.	Basis of Presentation and Significant Accounting Policies (continued).

WARRANTS LIABILITY. In October 2011, the Company issued 1,523,370 warrants (the 2011 warrants) to purchase shares of the Company’s common stock in connection with a registered direct offering. During the periods that the 2011 warrants were outstanding, the Company accounted for these warrants as a liability measured at fair value due to a provision included in the warrants agreement that provided the warrants holders with an option to require the Company (or its successor) to purchase their warrants for cash in an amount equal to their Black-Scholes Option Pricing Model (the Black-Scholes Model) value, in the event that certain fundamental transactions, as defined, occurred. The fair value of the warrants liability was estimated using the Black-Scholes Model which required inputs such as the expected term of the warrants, share price volatility and risk-free interest rate. These assumptions were reviewed on a quarterly basis and changes in the estimated fair value of the outstanding warrants were recognized each reporting period in the “Change in fair value of warrants liability” line in the consolidated statement of operations. At March 31, 2017, 763,913 of the 2011 warrants remained outstanding. All unexercised 2011 warrants expired on May 2, 2017. See Note 3.

STOCK-BASED COMPENSATION. The Company recognizes expense in the consolidated statement of operations for the fair value of all stock-based payments to employees, directors and consultants, including grants of stock options and other share-based awards. For stock options, the Company uses the Black-Scholes option valuation model, the single-option award approach, and the straight-line attribution method. Using this approach, compensation cost is amortized on a straight-line basis over the vesting period of each respective stock option, generally one to three years. Forfeitures are recognized as a reduction of share-based compensation expense as they occur.

As of March 31, 2018, there were outstanding stock options to purchase 6,902,500 shares of common stock, of which stock options to purchase 3,616,662 shares of common stock were exercisable as of March 31, 2018.

For the three-month periods ended March 31, 2018 and 2017, the Company recorded stock-based compensation expense as follows:


	Three months ended March 31,
	2018		2017
Research and development	$	294,315	$	206,352
General and administrative		677,025		547,792

Total stock-based compensation	$	971,340	$	754,144

COMPREHENSIVE INCOME (LOSS). U.S. GAAP require that all components of comprehensive income (loss) be reported in the financial statements in the period in which they are recognized. Comprehensive income (loss) is net income (loss), plus certain other items that are recorded directly into stockholders’ equity. The Company’s comprehensive loss is shown on the Consolidated Statement of Operations and Comprehensive Loss as of March 31, 2018 and is comprised of net unrealized losses on the Company’s available-for-sale securities. For December 31, 2017 and all prior periods, the Company’s net loss equaled comprehensive loss, since the Company had no items which were considered other comprehensive income (loss).

2.	Basis of Presentation and Significant Accounting Policies (continued).

NET LOSS PER SHARE. Basic loss per share is computed by dividing net loss for the period by the weighted average number of common shares outstanding during the period. The calculation of basic and diluted net loss per share is the same for all periods presented, as the effect of potential common stock equivalents is anti-dilutive due to the Company’s net loss position for all periods presented. The potential shares, which are excluded from the determination of basic and diluted net loss per share as their effect is anti-dilutive, are as follows:


	March 31,
	2018		2017
Options to purchase common stock		6,902,500		6,088,333
Warrants to purchase common stock		—		2,407,663
Unvested restricted stock		—		26,667

Potential equivalent common stock excluded		6,902,500		8,522,663

Potentially dilutive options to purchase common stock as of March 31, 2018 have exercise prices ranging from $0.79 to $4.64. Potentially dilutive options to purchase common stock as of March 31, 2017 had exercise prices ranging from $0.47 to $4.64.

RECENTLY ISSUED ACCOUNTING STANDARDS. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), which requires an entity to recognize assets and liabilities arising from a lease for both financing and operating leases. The ASU will also require new qualitative and quantitative disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, with early adoption permitted. The Company is currently evaluating the impact this accounting standard will have on its consolidated financial statements.

In May 2017, the FASB issued ASU No. 2017-09, Compensation – Stock Compensation (Topic 718): Scope of Modification Accounting to clarify when to account for a change to the terms or conditions of a share-based payment award as a modification. Under this new guidance, modification accounting is required if the fair value, vesting conditions, or classification of the award changes as a result of the change in terms or conditions. ASU 2017-09 is effective for all entities for annual reporting periods beginning after December 15, 2017, including interim reporting periods within each annual reporting period, applied prospectively on or after the effective date. The Company adopted this standard in the first quarter of 2018. The adoption of this standard did not have a material impact on the Company’s consolidated financial statements.

RECLASSIFICATIONS. Certain prior year amounts in the consolidated financial statements have been reclassified to conform to the current year presentation.

3.	Warrants Liability, at Fair Value.

2011 Warrants

The Company allocated approximately $1.3 million of proceeds from its October 2011 registered direct offering to the fair value of common stock purchase warrants issued in connection with the offering that were classified as a liability (the 2011 warrants). The 2011 warrants were classified as a liability because of provisions in such warrants that allowed for the net cash settlement of such warrants in the event of certain fundamental transactions (as defined in the warrant agreement). During the period that the 2011 warrants were outstanding, the valuation of the 2011 warrants was determined using the Black-Scholes Model. This model uses inputs such as the underlying price of the shares issued when the warrant is exercised, volatility, risk free interest rate and expected life of the instrument. The Company had determined that the 2011 warrants liability should be classified within Level 3 of the fair value hierarchy by evaluating each input for the Black-Scholes Model against the fair value hierarchy criteria and using the lowest level of input as the basis for the fair value classification. There are six inputs: closing price of the Company’s common stock on the day of evaluation; the exercise price of the warrants; the remaining term of the warrants; the volatility of the Company’s common stock; annual rate of dividends; and the risk-free rate of return. Of those inputs, the exercise price of the warrants and the remaining term were readily observable in the warrants agreement. The annual rate of dividends was based on the Company’s historical practice of not granting dividends. The closing price of the Company’s common stock would fall under Level 1 of the fair value hierarchy as it is a quoted price in an active market. The risk-free rate of return was a Level 2 input, while the historical volatility was a Level 3 input in accordance with the fair value accounting guidance. Since the lowest level input was a Level 3, the Company determined the 2011 warrants liability were most appropriately classified within Level 3 of the fair value hierarchy. This liability was subject to a fair value mark-to-market adjustment each reporting period. All unexercised 2011 warrants expired on May 2, 2017.

The calculated value of the 2011 warrants liability was determined using the Black-Scholes Model with the following assumptions:


	March 31, 2017
Risk free interest rate		1.03	%
Expected term		0.09 years
Expected volatility		110	%
Expected dividend yield		0	%
Expected forfeiture rate		0	%

The following table rolls forward the fair value of the Company’s warrants liability activity for the three-month period ended March 31, 2017:


	Three months ended March 31, 2017
Fair value, beginning of period	$	122,226
Issuance of warrants		—
Exercise of warrants		—
Change in fair value		397,235

Fair value, end of period	$	519,461

On May 2, 2017, the outstanding and unexercised 2011 warrants expired. During the three months ended March 31, 2017, none of the 2011 warrants were exercised.

4.	Short-term Investments.

Short-term investments by security type were as follows:


	Amortized cost		Gross Unrealized Gains		Gross Unrealized Losses			Estimated Fair Value
At March 31, 2018:
Short-term bond fund	$	26,555,853	$	—	$	(58,861	)	$	26,496,992
U.S. Treasuries		31,867,412		—		(21,826	)		31,845,586

Total	$	58,423,265	$	—	$	(80,687	)	$	58,342,578

At December 31, 2017:
Short-term bond fund	$	26,487,281	$	29,430	$	—		$	26,516,711

The Company has classified its U.S. Treasuries as available-for-sale securities and, as such, they are reported at fair value with unrealized gain and losses included in comprehensive loss in stockholders’ equity and realized gain and losses, included in other income, net. There were no realized gains or losses from available-for-sale securities for the three months ended March 31, 2018 or 2017.

Certain U.S. Treasuries at March 31, 2018 had fair values less than their amortized costs and, therefore, contained unrealized losses. Given that the Company has no intent to sell the U.S. Treasuries until a recovery of its fair value, which may be at maturity, and there are no current requirements to sell any of these securities, the Company did not consider these investments to be other-than-temporarily impaired as of March 31, 2018. The Company anticipates full recovery of amortized costs with respect to these investments at maturity. The duration of time the U.S. Treasuries have been in a continuous unrealized loss position as of March 31, 2018 was less than 3 months.

5.	Prepaid Expenses and Other Current Assets.

Prepaid expenses and other current assets consist of the following:


	March 31, 2018		December 31, 2017
Prepaid research fees	$	249,094	$	388,977
Prepaid insurance		501,181		638,139
Prepaid pre-commercialization fees		76,900		65,000
Prepaid subscription fees		92,916		23,347
Prepaid rent		20,981		—
Other		51,756		58,281

Total prepaid expenses and other current assets	$	992,828	$	1,173,744

6.	Property and Equipment, net.

Property and equipment, net consists of the following:


	March 31, 2018			December 31, 2017
Computer equipment	$	27,915		$	27,915
Furniture and equipment		169,931			169,931
Leasehold improvements		152,708			152,708

		350,554			350,554
Less: Accumulated depreciation		(167,184	)		(159,169	)

Total property and equipment, net	$	183,370		$	191,385

Depreciation expense was $8,015 and $12,958, respectively, for the three-month periods ended March 31, 2018 and 2017 respectively.

7.	Accrued Expenses and Other Liabilities.

Accrued expenses and other liabilities consist of the following:


	March 31, 2018		December 31, 2017
Accrued preclinical and clinical trial expenses	$	990,080	$	970,649
Accrued professional fees		558,260		227,457
Accrued compensation and benefits		54,548		821,935
Accrued license fees		278,750		252,500
Deferred rent and lease incentive		25,597		24,011
Other		19,136		24,035

Current accrued expenses and other liabilities		1,926,371		2,320,587

Deferred rent and lease incentive - non-current		150,395		157,456

Non-current accrued expenses and other liabilities		150,395		157,456

Total accrued expenses and other liabilities	$	2,076,766	$	2,478,043

8.	Commitments and Contingencies.

LICENSE AGREEMENT WITH NORTHWESTERN UNIVERSITY. On August 27, 2009, the Company entered into a license agreement with Northwestern University (Northwestern), under which it acquired worldwide rights to commercialize new GABA aminotransferase inhibitors and derivatives of vigabatrin that have been discovered by Northwestern. Under the terms of the license agreement, Northwestern granted the Company an exclusive worldwide license to certain composition of matter patents related to the new class of inhibitors and a patent application relating to derivatives of vigabatrin. The Company has identified and designated the lead compound under this license as CPP-115.

Under the license agreement with Northwestern, the Company is responsible for continued research and development of any resulting product candidates. As of March 31, 2018, the Company has paid $424,885 in connection with the license and has accrued license fees of $278,750 in the accompanying March 31, 2018 consolidated balance sheet for expenses, maintenance fees and milestones. In addition, the Company is obligated to pay certain milestone payments in future years relating to clinical development activities with respect to CPP-115, and royalties on any products resulting from the license agreement, if the Company does not cancel the license agreement. The next milestone payment of $300,000 is due on the earlier of successful completion of the first Phase 3 clinical trial for CPP-115 or August 27, 2018.

LICENSE AGREEMENT WITH NEW YORK UNIVERSITY AND THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH. On December 13, 2011, the Company entered into a license agreement with New York University (NYU) and the Feinstein Institute for Medical Research (FIMR) under which it acquired worldwide rights to commercialize GABA aminotransferase inhibitors in the treatment for Tourette’s Disorder. The Company is obligated to pay certain milestone payments in future years relating to clinical development activities and royalties on any products resulting from the license agreement.

LICENSE AGREEMENT WITH BIOMARIN. On October 26, 2012, the Company entered into a license agreement with BioMarin Pharmaceutical, Inc. (BioMarin) for the North American rights to Firdapse^®.

Under the License Agreement, the Company has agreed to pay: (i) royalties to BioMarin for seven years from the first commercial sale of Firdapse^® equal to 7% of net sales (as defined in the license agreement) in North America for any calendar year for sales up to $100 million, and 10% of net sales in North America in any calendar year in excess of $100 million; and (ii) royalties to the third-party licensor of the rights sublicensed to the Company for seven years from the first commercial sale of Firdapse^® equal to 7% of net sales (as defined in the license agreement between BioMarin and the third-party licensor) in any calendar year.

8.	Commitments and Contingencies (continued).

Under the Company’s license agreement with BioMarin, the Company has agreed to pay certain milestone payments that BioMarin is obligated to pay to both a third-party licensor of the rights that have been sublicensed to the Company and to the former stockholders of Huxley Pharmaceuticals (“Huxley”) under an earlier stock purchase agreement between BioMarin and the former Huxley stockholders. These milestones aggregate (i) approximately $2.6 million due upon acceptance by the FDA of a filing of an NDA for Firdapse^® for the treatment of LEMS or CMS (approximately $150,000 of which will be due to the third party licensor and approximately $2,425,000 of which will be due to the former Huxley stockholders), and (ii) approximately $7.2 million due upon the unconditional approval by the FDA of an NDA for Firdapse^® for the treatment of LEMS (approximately $3.0 million of which will be due to the third party licensor and approximately $4.2 million of which will be due to the former Huxley stockholders). However, under BioMarin’s agreement with the former Huxley stockholders (and under the Company’s license agreement with BioMarin), BioMarin’s obligation to pay the milestone payments due to the former Huxley stockholders (and the Company’s corresponding obligation to pay such milestone payments) expired because the milestones were not satisfied by April 20, 2018.

BioMarin has recently advised the Company that the former Huxley stockholders may take legal action seeking payment of the milestone payments due to them from BioMarin if these milestones are achieved after April 20, 2018, notwithstanding the express termination date in the agreements. BioMarin has also advised the Company that the Company could become involved in any such legal action. While it is too early to determine how this matter will affect the Company, based on currently available information the Company does not believe that this matter will have a material adverse effect on the Company’s financial position or results of operations.

The Company also agreed to share in the cost of certain post-marketing studies being conducted by BioMarin, and, as of March 31, 2018, the Company had paid BioMarin $3.8 million related to expenses in connection with Firdapse^® studies and trials.

AGREEMENTS FOR DRUG DEVELOPMENT, PRE-CLINICAL AND CLINICAL STUDIES. The Company has entered into agreements with contract manufacturers for the manufacture of drug and study placebo for the Company’s trials and studies, with contract research organizations (CRO) to conduct and monitor the Company’s trials and studies and with various entities for laboratories and other testing related to the Company’s trials and studies. The contractual terms of the agreements vary, but most require certain advances as well as payments based on the achievement of milestones. Further, these agreements are cancellable at any time, but obligate the Company to reimburse the providers for any time or costs incurred through the date of termination.

9.	Income Taxes.

The Company is subject to income taxes in the U.S. federal jurisdiction and various states jurisdictions. Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require significant judgment to apply. The Company is not subject to U.S. federal, state and local tax examinations by tax authorities for any years before 2014. If the Company were to subsequently record an unrecognized tax benefit, associated penalties and tax related interest expense would be reported as a component of income tax expense.

The Company’s net deferred tax asset has a 100% valuation allowance at March 31, 2018 and December 31, 2017 as the Company believes that it is more likely than not that the deferred tax asset will not be realized.

10.

Stockholders’ Equity.

2016 Shelf Registration Statement

On December 23, 2016, the Company filed a shelf Registration Statement on Form S-3 (the 2016 Shelf Registration Statement) with the SEC to sell up to approximately $33.8 million of common stock. The 2016 Shelf Registration Statement (file No. 333-215315) was declared effective by the SEC on January 9, 2017. No sales have been conducted to date under the 2016 Shelf Registration Statement.

2017 Shelf Registration Statement

On July 12, 2017, the Company filed a universal shelf Registration Statement on Form S-3 (the 2017 Shelf Registration Statement) with the SEC to sell up to $150 million of common stock, preferred stock, warrants to purchase common stock, or debt securities (including debt securities that may be convertible or exchangeable for common stock or other securities), which securities may be offered separately or together in units or multiple series. The 2017 Shelf Registration Statement (file No. 333-219259) was declared effective by the SEC on July 26, 2017. The Company has to date conducted the following sales of its securities under the 2017 Shelf Registration Statement:

(a)

On November 28, 2017, the Company filed a prospectus supplement and offered for sale 16,428,572 shares of its common stock at a price of $3.50 per share in an underwritten public offering. The Company received gross proceeds in the public offering of approximately $57.5 million before underwriting commission and incurred expenses of approximately $3.7 million.

As of March 31, 2018, there is approximately $92.5 million available for future sale under the 2017 Shelf Registration Statement.

11.

Stock Compensation.

Stock Options

During the three-month periods ended March 31, 2018 and 2017, the Company granted seven-year term options to purchase an aggregate of 1,772,500 and 1,520,000 shares, respectively, of the Company’s common stock to employees and directors. Option awards generally vest over a period of 1 to 3 years of continuous service. The Company recorded stock-based compensation related to stock options totaling $971,340 and $735,536 respectively, during the three-month periods ended March 31, 2018 and 2017. During the three-month periods ended March 31, 2018 and 2017, respectively, 744,998 and 255,000 options vested.

During the three months ended March 31, 2018, options to purchase 36,666 shares of the Company’s common stock were exercised, with proceeds of $33,032 to the Company. No options were exercised during the three months ended March 31, 2017.

As of March 31, 2018, there was approximately $4,810,000 of unrecognized compensation expense related to non-vested stock option awards granted under the 2006 and 2014 Stock Incentive Plans. The cost is expected to be recognized over a weighted average period of approximately 2.34 years.

Restricted Stock Units

No restricted stock units were granted during the three months ended March 31, 2018 and 2017. The Company recorded stock-based compensation related to restricted stock units totaling $0 and $18,608, during the three-month periods ended March 31, 2018 and 2017. All restricted stock units were vested as of December 31, 2017.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Introduction

Management’s Discussion and Analysis of Financial Condition and Results of Operations (MD&A) is intended to provide an understanding of our financial condition, changes in financial condition and results of operations. The discussion and analysis is organized as follows:

•

Overview. This section provides a general description of our business and information about the current status of our business that we believe is important in understanding our financial condition and results of operations.

•

Basis of Presentation. This section provides information about key accounting estimates and policies that we followed in preparing our consolidated financial statements for the first quarter of fiscal 2018.

•

Critical Accounting Policies and Estimates. This section discusses those accounting policies that are both considered important to our financial condition and results of operations, and require significant judgment and estimates on the part of management in their application. All of our significant accounting policies, including our critical accounting policies, are also summarized in the notes to our interim consolidated financial statements that are included in this report.

•

Results of Operations. This section provides an analysis of our results of operations for the three months ended March 31, 2018 as compared to the same period ended March 31, 2017.

•

Liquidity and Capital Resources. This section provides an analysis of our cash flows, capital resources, off-balance sheet arrangements and our outstanding commitments, if any.

•

Caution Concerning Forward-Looking Statements. This section discusses how certain forward-looking statements made throughout this MD&A and in other sections of this report are based on management’s present expectations about future events and are inherently susceptible to uncertainty and changes in circumstance.

Overview

We are a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. We currently have three drug candidates in development:

•

Firdapse®

In October 2012, we licensed the North American rights to Firdapse^®, a proprietary form of amifampridine phosphate, or chemically known as 3,4-diaminopyridine phosphate, from BioMarin Pharmaceutical Inc. (BioMarin). In August 2013, we were granted “breakthrough therapy designation” by the U.S. Food & Drug Administration (FDA) for Firdapse^® for the treatment of patients with Lambert-Eaton Myasthenic Syndrome, or LEMS, a rare and sometimes fatal autoimmune disease characterized by muscle weakness. Further, the FDA has granted Orphan Drug Designation for Firdapse^® for the treatment of patients with LEMS, Congenital Myasthenic Syndromes, or CMS and Myasthenia Gravis (MG).

The chemical entity, amifampridine (3,4-diaminopyridine, or 3,4-DAP), has never been approved by the FDA for any indication. Because amifampridine phosphate (Firdapse^®) has been granted Orphan Drug designation for the treatment of LEMS, CMS and MG by the FDA, the product is also eligible to receive seven years of marketing exclusivity for either or all of these indications. Further, if we are the first pharmaceutical company to obtain approval for an amifampridine product, of which there can be no assurance, we will be eligible to receive five years of marketing exclusivity with respect to the use of this product for any indication, running concurrently with the seven years of orphan marketing exclusivity described above (if both exclusivities are granted).

We previously sponsored a multi-center, randomized, placebo-controlled Phase 3 trial evaluating Firdapse^® for the treatment of LEMS. This Phase 3 trial, which involved 38 subjects, was designed as a randomized “withdrawal” trial in which all patients were treated with Firdapse^® during a 7 to 91-day run-in-period followed by treatment with either Firdapse^® or placebo over a two-week randomization period. The co-primary endpoints for this Phase 3 trial were the comparison of changes in patients randomized to continue Firdapse^® versus those who transitioned to placebo that occurred in both the quantitative myasthenia gravis score (QMG), which measures muscle strength, and subject global impression score (SGI), on which the subjects rate their global impression of the effects of a study treatment during the two-week randomization period. In September 2014, we reported positive top-line results from this Phase 3 trial, and the successful results of this study were published in 2016 in Muscle & Nerve (Muscle Nerve, 2016, 53(5):717-725).

During 2014, we established an expanded access program (EAP) to make Firdapse^® available to any patients diagnosed with LEMS, CMS, or Downbeat Nystagmus in the United States, who meet the inclusion and exclusion criteria, with Firdapse^® being provided to patients for free until sometime after new drug application (NDA) approval, should we receive such approval (of which there can be no assurance). We continue to inform neuromuscular physicians as to the availability of the Firdapse^® EAP and also to work with various rare disease advocacy organizations to inform patients and physicians about the program.

On December 17, 2015, we announced completion of the submission of an NDA for Firdapse^® for the treatment of LEMS and CMS. However, on February 17, 2016, we announced that we had received a “refusal to file” (RTF) letter from the FDA regarding our NDA submission. In early April 2016, we met with the FDA to obtain greater clarity regarding what would be required by the FDA to accept the Firdapse^® NDA for filing. Following the receipt of the formal minutes of that meeting, on April 26, 2016, we issued a press release reporting that the FDA had advised us that in addition to the results of our previously submitted multi-center, randomized, placebo-controlled Phase 3 trial, we would need to submit positive results from a second adequate and well-controlled study in patients with LEMS. Additionally, there was a requirement for us to perform several abuse liability studies for Firdapse^®.

In October 2016, we announced that we had reached an agreement with the FDA under a Special Protocol Assessment (SPA) for the protocol design, clinical endpoints, and statistical analysis approach to be taken in our second Phase 3 study evaluating Firdapse^® (amifampridine phosphate) for the symptomatic treatment of LEMS. A SPA is a process by which sponsors ask the FDA to evaluate the protocol of a proposed clinical trial to determine whether it adequately addresses scientific and regulatory requirements for the purpose identified by the sponsor. A SPA agreement indicates FDA concurrence with the adequacy and acceptability of specific critical elements of protocol design, endpoints and analysis. Additionally, it provides a binding agreement with FDA’s review division that a pivotal trial design, conduct, and planned analysis adequately addresses the scientific and regulatory objectives in support of a regulatory submission for drug approval. However, the FDA may rescind a SPA agreement when the division director determines that a substantial scientific issue essential to determining the safety or efficacy of the product has been identified after the trial has begun.

Our second Phase 3 trial evaluating Firdapse^® for the treatment of LEMS (designated as LMS-003) was conducted at sites in Miami, Florida and Los Angeles, California. This double-blind, placebo-controlled withdrawal trial had the same co-primary endpoints as our first Phase 3 trial evaluating Firdapse^® for the treatment of LEMS. Further, the FDA allowed us to enroll patients from our expanded access program as study subjects in this second trial. Enrollment in this trial, which included 26 subjects, was completed in October 2017. Details of the Phase 3 clinical trial are available on www.clinicaltrials.gov (NCT02970162).

On November 27, 2017, we reported positive top-line results from the LMS-003 trial. This trial had two prospectively defined co-primary endpoints. The first of these, quantitative myasthenia gravis score (QMG), achieved a statistically significant p-value of 0.0004, and the second, subject global impression (SGI), achieved a statistically significant p-value of 0.0003. More importantly, a clinically significant difference of 6.4 points was observed between the Firdapse^® and placebo groups for the QMG endpoint. Firdapse^® was well tolerated and showed a similar safety profile to that seen in earlier studies. All p-values reported are based on the entire intent to treat (ITT) population of patients that enrolled in this trial.

The prospectively defined secondary endpoint for the physician’s clinical global impression of improvement (CGI-I) achieved statistical significance (p-value 0.0020). Further, the exploratory endpoints of triple timed up and go (3TUG, p-value 0.0112) and the evaluation of the QMG-Limb domains endpoint (p-value 0.0010) were also statistically significant. The exploratory endpoint of most bothersome symptom (MBS) (p-value 0.0572) was not significant, but showed a trend.

We were also required to conduct three pre-clinical abuse liability studies under the FDA guidance for “Assessment of Abuse Potential of Drugs” that was finalized in January 2017 (Self-Administration, Physical Dependence and Drug Discrimination). All three studies have been completed, and top-line results indicate that amifampridine phosphate does not exhibit abuse potential in these assessment models.

On February 12, 2018, after receipt of the minutes of our recently held Type C meeting with the FDA, we issued a press release reporting on the results of the meeting. Prior to the meeting, we had provided the FDA with our preliminary data package for our proposed NDA resubmission, including the positive top-line results from our LMS-003 trial, as well as the FDA-required abuse liability studies that we recently completed demonstrating that Firdapse^® does not have abuse liability potential. The minutes of the meeting reflect the FDA’s advice to us that our proposed filing package will be sufficient for resubmission of an NDA for Firdapse^®.

On March 29, 2018, we reported that we had resubmitted an NDA to the FDA for Firdapse^® for the symptomatic treatment of LEMS. There can be no assurance that our resubmitted NDA will be accepted for filing or approved.

Our original NDA submission for Firdapse^® included data and information (including data from a currently ongoing investigator treatment IND) providing evidence supporting the benefits of Firdapse^® for treating certain types of CMS, and requested that CMS be included in our initial label for Firdapse^®. To provide additional support for our submission of an NDA for Firdapse^® for the treatment of CMS, in October 2015 we initiated a small blinded clinical trial at four academic centers of up to 10 subjects in the pediatric CMS population, ages 2 to 17. However, after considering comments from the FDA, we determined to enroll both adult and pediatric subjects with CMS in this trial and to expand the number of subjects to be evaluated in the trial to an aggregate of approximately 20 subjects. We are currently conducting this study at trial sites around the United States and Canada, and we are currently working to add one or more additional sites outside the United States. Details of this trial are available on www.clinicaltrials.gov (NCT02562066).

Based on currently available information, we expect to complete enrollment in this trial before the end of 2018 and to report top-line results from this trial in the first quarter of 2019. There can be no assurance that any trial we perform for Firdapse^® for the treatment of CMS will be successful or whether any NDA or NDA supplement that we may submit for Firdapse^® for the treatment of CMS in the future will be filed by the FDA for review and approved.

We considered adding to the proposed label for our recently resubmitted NDA for Firdapse^® those limited types of congenital myasthenic syndromes (CMS) that are considered mechanistically similar to LEMS. However, after discussion with the FDA at the Type C meeting, and further consideration, we elected not to complicate the review of our NDA submission for Firdapse^® for the treatment of LEMS with this second indication. Once our currently ongoing CMS clinical trial is completed, and assuming the trial is successful, we plan to seek to add CMS to our label for Firdapse^® for a much broader population of CMS patients.

In February 2016, we announced the initiation of an investigator-sponsored, randomized, double-blind, placebo-controlled, crossover Phase 2/3 clinical trial evaluating the safety, tolerability and potential efficacy of Firdapse^® as a symptomatic treatment for patients with MuSK-MG. MuSK-MG is a particularly severe form of myasthenia gravis that affects about 3,000 to 4,800 patients in the U.S., for which there are no approved effective therapies and is therefore an unmet medical need. Seven patients participated in this proof-of-concept trial. We provided study drug, placebo and financial support for this study.

On March 15, 2017, we reported top-line results from this trial. Both of the co-primary efficacy endpoints of change from baseline (CFB) in total Quantitative Myasthenia Gravis (QMG) score (p=0.0003) and CFB in total Myasthenia Gravis Activities of Daily Living (MG-ADL) score (p=0.0006) were statistically and clinically significant in this trial. Several secondary efficacy measures also achieved statistical significance. Amifampridine phosphate was well tolerated in this population of patients.

On August 30, 2017, we announced that we had reached an agreement with the FDA on a SPA for the protocol design, clinical endpoints, and statistical analysis approach to be taken in our proposed Phase 3 registration trial evaluating the safety and efficacy of amifampridine phosphate treatment in patients with MuSK-MG. The protocol that the FDA has reviewed is for a multi-site, international (U.S. and Italy), double-blind, placebo-controlled, clinical trial that is targeted to enroll approximately 60 subjects diagnosed with MuSK-MG. The trial will employ a primary endpoint of Myasthenia Gravis Activities of Daily Living (MG-ADL) and a secondary endpoint of Quantitative Myasthenia Gravis Score (QMG). At the FDA’s request, the trial will also enroll up to 10 generalized myasthenia gravis patients who will be assessed with the same clinical endpoints, but achieving statistical significance in this subgroup of patients is not required and only summary statistics will be provided.

We initiated this trial in January 2018 and recently began enrolling subjects. We anticipate that it will take about 12 months to complete the enrollment for the trial and we expect to report top-line results from this trial in the first half of 2019. Details of this trial are available on www.clinicaltrials.gov (NCT03304054).

On November 21, 2017, we announced the initiation of a company-sponsored, proof-of-concept clinical trial evaluating safety, tolerability and efficacy of Firdapse^® as a symptomatic treatment for patients with Spinal Muscular Atrophy (SMA) Type 3. The study is being conducted by a team of researchers led by Lorenzo Maggi, MD, and Giovanni Baranello, MD, of the Fondazione Istituto Neurologico Carlo Besta in Milan, Italy, a major referral center for SMA patients. The study is designed as a randomized (1:1), double-blind, 2-period, 2-treatment, crossover, outpatient proof-of-concept study to evaluate the safety, tolerability and potential efficacy of amifampridine in ambulatory patients diagnosed with SMA Type 3. The study is planned to include approximately 12 patients, and we anticipate reporting top-line results from the study in the second half of 2019.

There can be no assurance that any trial that we initiate to evaluate Firdapse^® for MuSK-MG or SMA Type 3 will be successful. Further, there can also be no assurance that the FDA will ever approve Firdapse^® for these indications.

Finally, we may seek to evaluate Firdapse^® for the treatment of other rare, similar neuromuscular diseases, although we have not yet begun to develop clinical programs for these other indications, and all such programs are subject to the availability of funding. There can be no assurance that Firdapse^® will be an effective treatment for any other rare, similar neuromuscular diseases.

Prior to the receipt of the RTF letter, we had actively been taking steps to prepare for the commercialization of Firdapse^® in the United States. However, in light of the receipt of the RTF letter, in the first quarter of 2016 we put most of our commercialization activities on hold in order to conserve cash. During the fourth quarter of 2017, as we moved closer to the filing of an NDA for Firdapse^® for LEMS, we recommenced the development of our commercialization plans for Firdapse^®. We are also continuing to work with several rare disease advocacy organizations to help increase awareness of LEMS, CMS and MUSK-MG and to provide awareness and outreach support for the physicians who treat these rare diseases and the patients they treat.

•

CPP-115

We are developing CPP-115, a GABA aminotransferase inhibitor that, based on our preclinical studies to date, we believe is a more potent form of vigabatrin, and may have fewer side effects (e.g., visual field defects) than those associated with vigabatrin. We are hoping to develop CPP-115 for the treatment of refractory infantile spasms and possibly for the treatment of adult refractory patients with Tourette’s Disorder. CPP-115 has been granted Orphan Drug Designation by the FDA for the treatment of infantile spasms and Orphan Medicinal Product Designation in the European Union, or E.U., for West syndrome (a form of infantile spasms).

We are currently refining our development plans for this product. We are also working with one or more potential investigators who have expressed an interest in evaluating our product for particular indications (particularly infantile spasms).

We are also continuing our efforts to seek a partner to work with us in furthering the development of CPP-115. However, no agreements have been entered into to date.

There can be no assurance that we will ever successfully commercialize CPP-115.

•

Generic Sabril®

In September 2015, we announced the initiation of a project to develop generic versions of Sabril^® (vigabatrin) in two dosage forms: tablets and powder sachets. Sabril^® is marketed by Lundbeck Inc. in the United States in both dosage forms for the treatment of infantile spasms and refractory complex partial seizures. There can be no assurance that we will be successful in these efforts or that any abbreviated new drug applications (ANDAs) that we submit for vigabatrin will be accepted for review or approved.

We are also continuing our efforts to seek a partner to work with us in furthering the development of generic Sabril^®. However, no agreements have been entered into to date.

There can be no assurance that we will ever successfully commercialize a generic version of Sabril®.

Available Capital Resources

Based on forecasts of available cash, we believe that we have sufficient resources to support our currently anticipated operations through 2019 (without considering revenues and cash receipts that may be received in 2019 if we are successful in obtaining an approval for Firdapse^® and launching the product in 2019, of which there can be no assurance). There can be no assurance that we will ever be in a position to commercialize any of our drug candidates or that we will obtain any additional funding that we may require in the future. See “Liquidity and Capital Resources” below for further information on our liquidity and cash flow.

Basis of presentation

Revenues.

We are a development stage company and have had no revenues from product sales to date. We will not have revenues from product sales until such time as we receive approval of our drug candidates, successfully commercialize our products or enter into a licensing agreement which may include up-front licensing fees, of which there can be no assurance.

Research and Development Expenses.

Our research and development expenses consist of costs incurred for company-sponsored research and development activities, as well as support for selected investigator-sponsored research. The major components of research and development costs include preclinical study costs, clinical manufacturing costs, clinical study and trial expenses, insurance coverage for clinical trials, consulting, scientific advisors and other third-party costs, salaries and employee benefits, stock-based compensation expense, supplies and materials and allocations of various overhead costs related to our product development efforts. To date, all of our research and development resources have been devoted to the development of CPP-109 (our version of vigabatrin), CPP-115, and Firdapse^®, and we expect this to continue for the foreseeable future.

Our cost accruals for clinical studies and trials are based on estimates of the services received and efforts expended pursuant to contracts with numerous clinical study and trial sites and clinical research organizations (CROs). In the normal course of our business we contract with third parties to perform various clinical study and trial activities in the on-going development of potential products. The financial terms of these agreements are subject to negotiation and vary from contract to contract and may result in uneven payment flows. Payments under the contracts depend on factors such as the achievement of certain events or milestones, the successful enrollment of patients, the allocation of responsibilities among the parties to the agreement, and the completion of portions of the clinical study or trial or similar conditions. The objective of our accrual policy is to match the recording of expenses in our consolidated financial statements to the actual services received and efforts expended. As such, expense accruals related to preclinical and clinical studies or trials are recognized based on our estimate of the degree of completion of the event or events specified in the specific study or trial contract. We monitor service provider activities to the extent possible; however, if we underestimate activity levels associated with various studies or trials at a given point in time, we could be required to record significant additional research and development expenses in future periods. Preclinical and clinical study and trial activities require significant up-front expenditures. We anticipate paying significant portions of a study or trial’s cost before such study or trial begins, and incurring additional expenditures as the study or trial progresses and reaches certain milestones.

Selling and Marketing Expenses.

We do not currently have any selling or marketing expenses. We had been incurring costs tied to our future sales and marketing efforts for Firdapse^®. However, during the first quarter of 2016, following the receipt of the RTF letter, we put most of these activities on hold in order to conserve cash. In the fourth quarter of 2017, we recommenced the developing of our commercialization plans for Firdapse^® as we moved closer to the submission of an NDA for Firdapse^®. Pre-commercialization costs are included in general and administrative expenses.

General and Administrative Expenses.

Our general and administrative expenses consist primarily of salaries and personnel expenses for accounting, corporate, compliance and administrative functions. Other costs include administrative facility costs, regulatory fees, insurance, pre-commercialization costs, and professional fees for legal, information technology, accounting and consulting services.

Stock-Based Compensation.

We recognize expense for the fair value of all stock-based awards to employees, directors, and consultants in accordance with U.S. GAAP. For stock options, we use the Black-Scholes option valuation model in calculating the fair value of the awards.

Warrants Liability.

We issued warrants to purchase shares of our common stock as part of an equity financing that we completed in October 2011. In accordance with U.S. GAAP, we recorded the fair value of those warrants as a liability in the consolidated balance sheet using a Black-Scholes option-pricing model. We remeasured the fair value of this warrants liability at each reporting date until the warrants were exercised or until the unexercised warrants expired on May 2, 2017. Changes in the fair value of the warrants liability were reported in the consolidated statements of operations as income or expense. The fair value of the warrants liability was subject to significant fluctuation over the life of these warrants based on changes in the inputs to the Black-Scholes option-pricing model, including our common stock price, expected volatility, expected term, the risk-free interest rate and dividend yield.

Income Taxes.

We have incurred operating losses since inception. Our net deferred tax asset has a 100% valuation allowance as of March 31, 2018 and December 31, 2017, as we believe it is more likely than not that the deferred tax asset will not be realized. If an ownership change, as defined under Internal Revenue Code Section 382, occurs, the use of any of our carry-forward tax losses may be subject to limitation.

As required by ASC 740, Income Taxes, we would recognize the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority.

Recently Issued Accounting Standards.

For discussion of recently issued accounting standards, please see Note 2, “Basis of Presentation and Significant Accounting Policies,” in the interim consolidated financial statements included in this report.

Non-GAAP Financial Measures.

We prepare our consolidated financial statements and footnotes thereto which accompany this report in accordance with U.S. GAAP (GAAP). To supplement our financial results presented on a GAAP basis, we may use non-GAAP financial measures in our reports filed with the Commission and/or in our communications with investors. Non-GAAP measures are provided as additional information and not as an alternative to our consolidated financial statements presented in accordance with GAAP. Our non-GAAP financial measures are intended to enhance an overall understanding of our current financial performance. We believe that the non-GAAP financial measures that we present provide investors and prospective investors with an alternative method for assessing our operating results in a manner that we believe is focused on the performance of ongoing operations and provide a more consistent basis for comparison between periods.

The non-GAAP financial measure that we have historically presented excludes from the calculation of net loss the expense (or the income) associated with the change in fair value of the liability-classified warrants. Further, we have historically reported non-GAAP net loss per share, which is calculated by dividing non-GAAP net loss by the weighted average common shares outstanding.

Any non-GAAP financial measures that we report should not be considered in isolation or as a substitute for comparable GAAP accounting, and investors should read them in conjunction with our consolidated financial statements and notes thereto prepared in accordance with GAAP. Finally, the non-GAAP measures of net loss that we may use may be different from, and not directly comparable to, similarly titled measures used by other companies.

Critical Accounting Policies and Estimates

Our discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with GAAP. The preparation of these consolidated financial statements requires us to make judgments, estimates, and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and disclosures of contingent assets and liabilities. For a full discussion of our accounting policies, please refer to Note 2 on the Financial Statements included in our 2017 Annual Report on Form 10-K filed with the SEC. Our most critical accounting policies and estimates include: accounting for research and development expenses and stock-based compensation, measurement of fair value, fair value of warrants liability, income taxes and reserves. We continually evaluate our judgments, estimates and assumptions. We base our estimates on the terms of underlying agreements, our expected course of development, historical experience and other factors that we believe are reasonable based on the circumstances, the results of which form our management’s basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates. There have been no material changes to our critical accounting policies and estimates from the information provided in Part II, Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our 2017 Annual Report on Form 10-K.

Results of Operations

Revenues.

We had no revenues for the three-month periods ended March 31, 2018 and 2017.

Research and Development Expenses.

Research and development expenses for the three-month periods ended March 31, 2018 and 2017 were $3,259,042 and $2,813,929, respectively, including stock-based compensation expense in each of the three-month periods of $294,315 and $206,352, respectively. Research and development expenses, in the aggregate, represented approximately 55% and 60% of total operating costs and expenses for the three-month periods ended March 31, 2018 and 2017. The stock-based compensation is non-cash and relates to the expense of stock options awards to certain employees.

Expenses for research and development for the three months ended March 31, 2018, excluding stock-based compensation, increased compared to amounts expended in the same period in 2017. The increase in research and development expenses for the three months ended March 31, 2018 when compared to the same period in 2017 is primarily due to an increase in consulting expenses as we prepared to submit our NDA for Firdapse^® during March 2018, offset by decreases in clinical expenses, including related drug costs. We expect that research and development costs will continue to be substantial during the balance 2018 as we complete trials evaluating Firdapse^® for the treatment of CMS, MuSK-MG and SMA Type 3, continue our Expanded Access Program for Firdapse^®, continue our other development programs and prosecute our recently submitted NDA for Firdapse^® for LEMS, assuming it is filed by the FDA.

Selling and Marketing Expenses.

We had no selling expenses for the three-month periods ended March 31, 2018 and 2017. In 2016, we had been incurring costs tied to our future sales and marking efforts for Firdapse^®. However, during the first quarter of 2016, following the receipt of the RTF letter, we put most of these activities on hold in order to conserve cash. During the fourth quarter of 2017, as we moved closer to an NDA submission for Firdapse^®, we restarted the development of our commercialization plans for Firdapse^®. Pre-commercialization costs are included in general and administrative expenses.

General and Administrative Expenses.

General and administrative expenses for the three months ended March 31, 2018 and 2017 were $2,674,398 and $1,865,942, respectively, including stock-based compensation expense in each of the three-month periods ending March 31, 2018 and 2017 of $677,025 and $547,792, respectively. General and administrative expenses represented 45% and 40% of total operating costs and expenses for the three months ended March 31, 2018 and 2017, respectively. The increase in general and administrative expenses for the three months ended March 31, 2018 when compared to the same period in 2017 is primarily due to increase in pre-commercialization expenses. We expect that general and administrative costs, including pre-commercialization costs, will continue to increase in 2018 compared with the general and administrative costs incurred in 2017, as we expand our operations and headcount to build up our infrastructure and commercial programs in preparation for a potential Firdapse^® launch in 2019.

As discussed above, pre-commercialization expenses are included in general and administrative expenses, and amounted to $630,991 and $166,205 respectively, for the three months ended March 31, 2018 and 2017.

Stock-Based Compensation.

Total stock-based compensation for the three-month periods ended March 31, 2018 and 2017 were $971,340 and $754,144, respectively. The increase in stock-based compensation for the three-month period ended March 31, 2018 when compared to the same period in 2017, is primarily due to the expense of options granted to employees and directors during the first quarter of 2018 in connection with 2017 year-end grants.

Change in Fair Value of Warrants Liability.

In connection with our October 2011 equity offering, we issued warrants to purchase an aggregate of 1,523,370 shares of common stock. As of May 2, 2017, all of the 2011 warrants were either exercised or had expired. The fair value of the portion of these warrants which remain outstanding was recorded in the liability section of the consolidated balance sheet and was estimated at $519,461 at March 31, 2017. The fair value of the warrants liability is determined at the end of each reporting period with the resulting gains or losses recorded as the change in fair value of warrants liability in the consolidated statements of operations.

No gain or loss was recognized for the three months ended March 31, 2018, as all 2011 warrants that were not exercised expired on May 2, 2017. For the three months ended March 31, 2017, we recognized a loss of $397,235, due to the change in the fair value of the warrants liability. The loss during the three months ended March 31, 2017 was principally a result of the increase of our stock price between December 31, 2016 and March 31, 2017.

Other Income, Net.

We reported other income, net in all periods relating to our investment of funds received from offerings of our securities. The increase in other income, net for the three months ended March 31, 2018 when compared to the same period in 2017 is primarily due to higher yields on investments and higher invested balances. Other income, net, consists of interest income, dividend income and unrealized and realized gain (loss) on trading securities. These proceeds are used to fund our drug development activities and our operations. Substantially all such funds were invested in short-term interest-bearing obligations and short-term bond funds.

Income Taxes.

We have incurred net operating losses since inception. For the three-month periods ended March 31, 2018 and 2017 we have applied a 100% valuation allowance against our deferred tax asset as we currently believe that it is more likely than not that the deferred tax asset will not be realized.

Net Loss.

Our net loss was $5,699,892 and $4,967,129, respectively, for the three months ended March 31, 2018 and 2017 ($0.06 and $0.06, respectively, per basic and diluted share).

Non-GAAP Net Loss.

Our non-GAAP net loss, which excludes for the three months ended March 31, 2018 and 2017 $0 and a loss of $397,235, respectively, associated with the change in the fair value of liability classified warrants, was $5,699,892 and $4,569,894 ($0.06 and $0.06 respectively, per basic and diluted share).

Liquidity and Capital Resources

Since our inception, we have financed our operations primarily through equity issuances, government grants, and an investment by a strategic purchaser. At March 31, 2018, we had cash and cash equivalents and short-term investments aggregating $77.9 million and working capital of $76.2 million. At December 31, 2017, we had cash and cash equivalents and short-term investments aggregating $84.0 million and working capital of $80.9 million. At March 31, 2018, substantially all of our cash and cash equivalents were deposited with one financial institution, and such balances were in excess of federally insured limits.

We have to date incurred operating losses, and we expect these losses to be substantial in the future as we continue our drug development programs and prepare for the commercialization of our drug candidates. We anticipate using current cash on hand to finance these activities. It will likely be some time before we obtain the necessary regulatory approvals to commercialize one or more of our product candidates in the United States.

At the present time, we will require additional funding for future studies or trials, other than those described as being on-going in this report. We may also require additional working capital to support our operations beyond that time, depending on when and if we are able to launch Firdapse^® and whether the results are cash flow positive. There can be no assurance as to the amount of any such funding that will be required for these purposes or whether any such funding will be available to us when it is required.

In that regard, our future funding requirements will depend on many factors, including:

•

the scope, rate of progress and cost of our clinical trials and other product development activities;

•

future clinical trial results;

•

the terms and timing of any collaborative, licensing and other arrangements that we may establish;

•

the cost and timing of regulatory approvals;

•

the cost and delays in product development as a result of any changes in regulatory oversight applicable to our products;

•

the cost and timing of establishing sales, marketing and distribution capabilities;

•

the effect of competition and market developments;

•

the cost of filing and potentially prosecuting, defending and enforcing any patent claims and other intellectual property rights; and

•

the extent to which we acquire or invest in other products.

We plan to raise additional funds that we may require in the future, through public or private equity offerings, debt financings, corporate collaborations or other means. We also may seek governmental grants for a portion of the required funding for our clinical trials and preclinical trials. We may also seek to raise capital to fund additional product development efforts or product acquisitions, even if we have sufficient funds for our planned operations. Any sale by us of additional equity or convertible debt securities could result in dilution to our stockholders. There can be no assurance that any such required additional funding will be available to us at all or available on terms acceptable to us. Further, to the extent that we raise additional funds through collaborative arrangements, it may be necessary to relinquish some rights to our technologies or grant sublicenses on terms that are not favorable to us. If we are not able to secure additional funding when needed, we may have to delay, reduce the scope of or eliminate one or more research and development programs, which could have an adverse effect on our business.

On July 12, 2017, we filed a shelf registration statement with the SEC to sell up to $150,000,000 of common stock, preferred stock, warrants to purchase common stock, debt securities and units consisting of one or more of such securities (the “2017 Shelf Registration Statement”). The 2017 Shelf Registration Statement (file no. 333-219259) was declared effective by the SEC on July 26, 2017. We have completed one offering under the 2017 Shelf Registration Statement:

•

On November 28, 2017, we raised net proceeds of approximately $53.8 million from the sale of 16,428,572 shares of our common stock.

On December 23, 2016, we filed a shelf registration statement with the SEC to sell up to $33,842,512 of common stock (the “2016 Shelf Registration Statement”). This shelf registration statement was declared effective by the SEC on January 9, 2017. We have made no sales under the 2016 Shelf Registration Statement.

At March 31, 2018, the full amount of our 2016 Shelf Registration Statement and $92,499,998 of our 2017 Shelf Registration Statement remains available for future sales. However, if our public float (the market value of our common stock held by non-affiliate stockholders) were to fall below $75 million, we would be subject to a further limitation under which we could sell no more than one-third (1/3) of our public float during any 12-month period. Further, the number of shares that we can sell at any one time may be limited under certain circumstances to 20% of the outstanding common stock under applicable NASDAQ marketplace rules.

Cash Flows

Net cash used in operating activities was $6,081,450 and $3,878,875, respectively, for the three-month periods ended March 31, 2018 and 2017. During the three months ended March 31, 2018, net cash used in operating activities was primarily attributable to our net loss of $5,699,892, and decreases of $1,140,552 in accounts payable, and $401,277 in accrued expenses and other liabilities. This was partially offset by a $180,916 decrease in prepaid expenses and other current assets and deposits, and $979,355 of other non-cash expenses. During the three months ended March 31, 2017, net cash used in operating activities was primarily attributable to our net loss of $4,967,129 and decreases of $15,248 in accounts payable and $178,917 in accrued expenses and other liabilities. This was partially offset by a $118,082 decrease in prepaid expenses and other current assets and deposits, $397,235 of non-cash change in fair value of warrants liability and $767,102 of other non-cash expenses. Such additional non-cash expenses consist of depreciation and stock-based compensation expense.

Net cash used in investing activities was $31,847,693 and $33,145, respectively, for the three-month periods ended March 31, 2018 and March 31, 2017, consisting primarily of purchases of short-term investments.

Net cash provided by financing activities during the three-month period ended March 31, 2018 was $33,032, consisting of proceeds from the exercise of options to purchase common stock. No cash was used in or provided by financing activities during the three-month period ended March 31, 2017.

Contractual Obligations

We have entered into the following contractual arrangements:

•

Payments to BioMarin and others under our license agreement with BioMarin. We have agreed to pay certain payments under to our license agreement with BioMarin.

•

Royalties: We have agreed to pay (i) royalties to BioMarin for seven years from the first commercial sale of Firdapse^® equal to 7% of net sales (as defined in the license agreement) in North America for any calendar year for sales up to $100 million, and 10% of net sales in North America in any calendar year in excess of $100 million; and (ii) royalties to the third-party licensor of the rights sublicensed to us for seven years from the first commercial sale of Firdapse^® equal to 7% of net sales (as defined in the license agreement between BioMarin and the third-party licensor) in any calendar year.

•

Milestone Payments: Under our license agreement with BioMarin, we have agreed to pay certain milestone payments that BioMarin is obligated to pay to both a third-party licensor of the rights that have been sublicensed to us and to the former stockholders of Huxley Pharmaceuticals (“Huxley”) under an earlier stock purchase agreement between BioMarin and the former Huxley stockholders. These milestones aggregate (i) approximately $2.6 million due upon acceptance by the FDA of a filing of an NDA for Firdapse^® for the treatment of LEMS or CMS (approximately $150,000 of which will be due to the third party licensor and approximately $2,425,000 of which will be due to the former Huxley stockholders), and (ii) approximately $7.2 million due upon the unconditional approval by the FDA of an NDA for Firdapse^® for the treatment of LEMS (approximately $3.0 million of which will be due to the third party licensor and approximately $4.2 million of which will be due to the former Huxley stockholders). However, under BioMarin’s agreement with the former Huxley stockholders (and under our license agreement with BioMarin), BioMarin’s obligation to pay the milestone payments due to the former Huxley stockholders (and our corresponding obligation to pay such milestone payments) expired because these milestones were not satisfied by April 20, 2018.

BioMarin has recently advised us that the former Huxley stockholders may take legal action seeking payment of the milestone payments due to them from BioMarin if these milestones are achieved after April 20, 2018, notwithstanding the express termination date in the agreements. BioMarin has also advised us that we could become involved in any such legal action. While it is too early to determine how this matter will affect us, based on currently available information we do not believe that this matter will have a material adverse effect on our financial position or results of operations.

•

Cost Sharing Payments. We have agreed to share in the cost of certain post-marketing studies conducted by BioMarin, and, as of March 31, 2018, we had paid BioMarin $3.8 million related to expenses in connection with Firdapse^® studies and trials.

•

Payments to Northwestern University under our license agreement. Under our license agreement with Northwestern, we have paid to date $424,885, had accrued liabilities of $278,750, at March 31, 2018 in the accompanying consolidated balance sheet, and owe certain milestone payments in future years if we do not cancel the license agreement. The next milestone payment of $300,000 is due on the earlier of successful completion of the first Phase 3 clinical trial of CPP-115 or August 27, 2018.

•

Employment agreements. We have entered into an employment agreement with our Chief Executive Officer that requires us to make base salary payments of approximately $525,000 in 2018. The agreement expires in November 2018.

•

Lease for office space. We operate our business in leased office space in Coral Gables, Florida. We currently lease approximately 5,200 square feet of office space for which we pay annual rent of approximately $200,000.

Off-Balance Sheet Arrangements.

We currently have no debt or capital leases. We have operating leases for our office facilities. We do not have any off-balance sheet arrangements as such term is defined in rules promulgated by the SEC.

Caution Concerning Forward-Looking Statements

This Current Report on Form 10-Q contains “forward-looking statements”, as that term is defined in the Private Securities Litigation Reform Act of 1995. These include statements regarding our expectations, beliefs, plans or objectives for future operations and anticipated results of operations. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, “believes”, “anticipates”, “proposes”, “plans”, “expects”, “intends”, “may”, and other similar expressions are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements. The forward-looking statements made in this report are based on current expectations that involve numerous risks and uncertainties.

The successful development and commercialization of our current drug candidates is highly uncertain. We cannot reasonably estimate or know the nature, timing, or estimated expenses of the efforts necessary to complete the development of, or the period in which material net cash inflows are expected to commence due to the numerous risks and uncertainties associated with developing such products, including the uncertainty of:

•

our estimates regarding anticipated capital requirements and our need for additional financing;

•

the risk that another pharmaceutical company will receive an approval for its formulation of 3,4-diaminopyridine (3,4-DAP) for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS), Congenital Myasthenic Syndromes (CMS), or any other indication, before we do;

•

whether the NDA that we recently submitted for Firdapse^®will be accepted for filing by the FDA, and, if accepted, whether it will be granted a priority review;

•

whether, even if the FDA accepts an NDA submission for Firdapse^®, such product will be determined to be safe and effective and approved for commercialization for any of the submitted indications;

•

whether the receipt of breakthrough therapy designation for Firdapse^®for LEMS will result in an expedited review of Firdapse^®by the FDA or affect the likelihood that the product will be found to be safe and effective;

•

whether as part of the FDA review of any NDA that we may submit for filing for Firdapse^®, the tradename Firdapse^®, which is the tradename used for the same product in Europe, will be approved for use for the product in the United States;

•

whether, assuming Firdapse^®is approved for commercialization, we will be able to develop or contract with a sales and marketing organization that can successfully market Firdapse^®while maintaining full compliance with applicable federal and state laws, rules and regulations;

•

whether the trials that we are undertaking to evaluate Firdapse^® for the treatment of CMS, MuSK-MG and SMA Type 3 or any other trials that we undertake in the future will be successful;

•

whether CPP-115 will be determined to be safe for humans;

•

whether CPP-115 will be determined to be effective for the treatment of infantile spasms, or possibly Tourette’s Disorder;

•

whether we can successfully design and complete bioequivalence studies of our versions of vigabatrin compared to Sabril^® that are acceptable to the FDA;

•

whether any ANDA that we submit for a generic version of Sabril^®will be accepted by the FDA for review and approved (and the timing of any such approval);

•

the scope, rate of progress and expense of our clinical trials and studies, pre-clinical studies, proof-of-concept studies, and our other drug development activities, and whether our trials and studies will be successful;

•

our ability to complete our trials and studies on a timely basis and within the budgets we establish for such trials and studies;

•

the scope, rate of progress and expense of our clinical trials and studies, pre-clinical studies, proof-of-concept studies, and our other development activities;

•

the ability of our third-party suppliers and contract manufacturers to maintain compliance with cGMP;

•

whether our estimates of the size of the market for our drug candidates will turn out to be accurate;

•

the pricing of our products that we may be able to achieve if we are granted the ability to commercialize our drug candidates; and

•

changes in the healthcare industry occasioned by any future repeal and replacement of the Affordable Care Act, in laws relating to the pricing of drug products, or changes in the healthcare industry generally;

Our current plans and objectives are based on assumptions relating to the development of our current drug candidates. Although we believe that our assumptions are reasonable, any of our assumptions could prove inaccurate. In light of the significant uncertainties inherent in the forward-looking statements we have made herein, which reflect our views only as of the date of this report, you should not place undue reliance upon such statements. We undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

ITEM 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISK

Our market risks during the three months ended March 31, 2018 have not materially changed from those discussed in Item 7A of our Annual Report on Form 10-K for the year ended December 31, 2017.

ITEM 4.

CONTROLS AND PROCEDURES

We have carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)). Based on such evaluation, our principal executive officer and principal financial officer have concluded that as of March 31, 2018, our disclosure controls and procedures were effective to ensure that the information required to be disclosed by us in the reports filed or submitted by us under the Exchange Act, was recorded, processed, summarized or reported within the time periods specified in the rules and regulations of the SEC, and include controls and procedures designed to ensure that information required to be disclosed by us in such reports was accumulated and communicated to management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosures.

During the three months ended March 31, 2018, there were no changes in our internal controls or in other factors that could have a material effect, or are reasonably likely to have a material effect, on our internal control over financial reporting.

PART II. OTHER INFORMATION

ITEM 1.

LEGAL PROCEEDINGS

The Company is not a party to any material legal proceedings.

ITEM 1A.

RISK FACTORS

There are many factors that affect our business, our financial condition, and the results of our operations. In addition to the information set forth in this quarterly report, you should carefully read and consider “Item 1A. Risk Factors” in Part I, and “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Part II, of our 2017 Annual Report on Form 10–K filed with the SEC, which contain a description of significant factors that might cause our actual results of operations in future periods to differ materially from those currently expected or desired.

ITEM 2.

UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None

ITEM 3.

DEFAULTS UPON SENIOR SECURITIES

None

ITEM 4.

MINE SAFETY DISCLOSURE

Not applicable

ITEM 5.

OTHER INFORMATION

None

ITEM 6.

EXHIBITS


31.1		Certification of Principal Executive Officer under Section 302 of the Sarbanes-Oxley Act of 2002

31.2		Certification of Principal Financial Officer under Section 302 of the Sarbanes-Oxley Act of 2002

32.1		Certification of Principal Executive Officer under Section 906 of the Sarbanes-Oxley Act of 2002

32.2		Certification of Principal Financial Officer under Section 906 of the Sarbanes-Oxley Act of 2002

101.INS		XBRL Instance Document

101.SCH		XBRL Taxonomy Extension Schema

101.CAL		XBRL Taxonomy Extension Calculation Linkbase

101.DEF		XBRL Taxonomy Extension Definition Linkbase

101.LAB		XBRL Taxonomy Extension Label Linkbase

101.PRE		XBRL Taxonomy Extension Presentation Linkbase

Exhibit Index


Exhibit Number		Description

31.1		Certification of Principal Executive Officer under Section 302 of the Sarbanes-Oxley Act of 2002

31.2		Certification of Principal Financial Officer under Section 302 of the Sarbanes-Oxley Act of 2002

32.1		Certification of Principal Executive Officer under Section 906 of the Sarbanes-Oxley Act of 2002

32.2		Certification of Principal Financial Officer under Section 906 of the Sarbanes-Oxley Act of 2002

101.INS		XBRL Instance Document

101.SCH		XBRL Taxonomy Extension Schema

101.CAL		XBRL Taxonomy Extension Calculation Linkbase

101.DEF		XBRL Taxonomy Extension Definition Linkbase

101.LAB		XBRL Taxonomy Extension Label Linkbase

101.PRE		XBRL Taxonomy Extension Presentation Linkbase

SIGNATURES

Pursuant to the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


Catalyst Pharmaceuticals, Inc.

By:		/s/ Alicia Grande
		Alicia Grande
		Vice President, Treasurer and Chief Financial Officer

Date: May 9, 2018

EX-31.1 2 d556138dex311.htm EX-31.1 EX-31.1

Exhibit 31.1

Certification of Principal Executive Officer

I, Patrick J. McEnany, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of Catalyst Pharmaceuticals, Inc.;

Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15(d)-15(f)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiary, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):

all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 9, 2018

/s/ Patrick J. McEnany

Patrick J. McEnany

Chief Executive Officer

(Principal Executive Officer)

EX-31.2 3 d556138dex312.htm EX-31.2 EX-31.2

Exhibit 31.2

Certification of Principal Financial Officer

I, Alicia Grande, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of Catalyst Pharmaceuticals, Inc.;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 9, 2018

/s/ Alicia Grande

Alicia Grande

Chief Financial Officer

(Principal Financial Officer)

EX-32.1 4 d556138dex321.htm EX-32.1 EX-32.1

Exhibit 32.1

Certification Required by 18 U.S.C. Section 1350

(as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002)

I, Patrick J. McEnany as Principal Executive Officer of Catalyst Pharmaceuticals, Inc. (the “Company”), certify, pursuant to 18 U.S.C. Section 1350 (as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002), that to my knowledge:

1.	the accompanying Quarterly Report on Form 10-Q of the Company for the quarterly period ended March 31, 2018 (the “Report”), filed with the U.S. Securities and Exchange Commission, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

2.	the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

EX-32.2 5 d556138dex322.htm EX-32.2 EX-32.2

Exhibit 32.2

Certification Required by 18 U.S.C. Section 1350

(as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002)

I, Alicia Grande as Principal Financial Officer of Catalyst Pharmaceuticals, Inc. (the “Company”), certify, pursuant to 18 U.S.C. Section 1350 (as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002), that to my knowledge:

1.	the accompanying Quarterly Report on Form 10-Q of the Company for the quarterly period ended March 31, 2018 (the “Report”), filed with the U.S. Securities and Exchange Commission, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

2.	the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

EX-101.INS 6 cprx-20180331.xml XBRL INSTANCE DOCUMENT

13893064

122226

33800000

3.50

102596164 150000000

9981044

519461

1926371

2076766

78935997

558260

150395

167184

208426045

805023

-21826

79128255

58342578

58423265

19600591

150000000

102586164

0.001

102586164

102586

25597

8888

54548

2881789

79128255

2731394

19136

150395

51756

0.001

5000000

992828

20981

501181

183370

350554

-132260339

3616662

6902500

58342578

76246466

249094 990080 76900 278750 92916

4810000

19343497

26496992

31845586

31867412

31845586

26496992

26555853

26496992

27915

169931

152708

300000 278750

763913

208426045

-21826

102586

-132260339

3800000

2320587

2478043

85187157

227457

157456

159169

207421710

1945575

85387430

57496702

150000000

102549498

0.001

102549498

102549

24011

8888

821935

4423618

85387430

4266162

24035

157456

58281

0.001

5000000

1173744

638139

191385

350554

-126560447

26516711

80963812

388977 970649 65000 252500 23347

56820688

26516711

26487281

26516711

27915

169931

152708

207421710

102549

-126560447

3700000

57500000

16428572

1300000

1523370 1.00

29430

false

<div> <table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr style="page-break-inside:avoid"> <td width="8%" valign="top" align="left">7.</td> <td align="left" valign="top">Accrued Expenses and Other Liabilities.</td> </tr> </table> Accrued expenses and other liabilities consist of the following:   <table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="66%"></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"> March 31, 2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"> December 31, 2017</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Accrued preclinical and clinical trial expenses </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">990,080</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">970,649</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Accrued professional fees </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">558,260</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">227,457</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Accrued compensation and benefits </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">54,548</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">821,935</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Accrued license fees </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">278,750</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">252,500</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Deferred rent and lease incentive </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">25,597</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">24,011</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Other </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">19,136</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">24,035</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Current accrued expenses and other liabilities </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,926,371</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,320,587</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Deferred rent and lease incentive - non-current </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">150,395</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">157,456</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Non-current accrued expenses and other liabilities </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">150,395</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">157,456</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Total accrued expenses and other liabilities </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,076,766</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,478,043</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

6902500

971340

<div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="PAGE-BREAK-INSIDE: avoid"> <td valign="top" width="8%" align="left">2.</td> <td valign="top" align="left">Basis of Presentation and Significant Accounting Policies.</td> </tr> </table>   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="PAGE-BREAK-INSIDE: avoid"> <td width="8%"> </td> <td valign="top" width="9%" align="left">a.</td> <td valign="top" align="left">INTERIM FINANCIAL STATEMENTS. The accompanying unaudited interim consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP), and pursuant to the rules and regulations of the Securities and Exchange Commission (SEC) for reporting of interim financial information. Pursuant to such rules and regulations, certain information and note disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been omitted. The consolidated balance sheet as of December 31, 2017 included in this Form 10-Q was derived from the audited financial statements and does not include all disclosures required by U.S. GAAP.</td> </tr> </table> In the opinion of management, the accompanying unaudited interim consolidated financial statements of the Company contain all adjustments (consisting of only normal recurring adjustments) necessary to present fairly the financial position of the Company as of the dates and for the periods presented. Accordingly, these consolidated statements should be read in conjunction with the financial statements and notes thereto for the year ended December 31, 2017 included in the 2017 Annual Report on Form 10-K filed by the Company with the SEC. The results of operations for the three months ended March 31, 2018 are not necessarily indicative of the results to be expected for any future period or for the full 2018 fiscal year. <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="PAGE-BREAK-INSIDE: avoid"> <td width="8%"> </td> <td valign="top" width="9%" align="left">b.</td> <td valign="top" align="left">PRINCIPLES OF CONSOLIDATION. The consolidated financial statements include the Company’s accounts and those of its wholly-owned subsidiary Catalyst Pharmaceuticals Ireland, Ltd. (“Catalyst Ireland”). All intercompany accounts and transactions have been eliminated in consolidation. Catalyst Ireland was organized in 2017.</td> </tr> </table>   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="PAGE-BREAK-INSIDE: avoid"> <td width="8%"> </td> <td valign="top" width="9%" align="left">c.</td> <td valign="top" align="left">USE OF ESTIMATES. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.</td> </tr> </table>   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="PAGE-BREAK-INSIDE: avoid"> <td width="8%"> </td> <td valign="top" width="9%" align="left">d.</td> <td valign="top" align="left">CASH AND CASH EQUIVALENTS. The Company considers all highly liquid instruments purchased with an original maturity of three months or less to be cash equivalents. Cash equivalents consist mainly of money market funds. The Company has substantially all of its cash and cash equivalents deposited with one financial institution. These amounts at times may exceed federally insured limits.</td> </tr> </table>   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="PAGE-BREAK-INSIDE: avoid"> <td width="8%"> </td> <td valign="top" width="9%" align="left">e.</td> <td valign="top" align="left">SHORT-TERM INVESTMENTS. The Company invests in short-term high credit-quality funds in order to obtain higher yields on its cash available for investments. At March 31, 2018 short-term investments consisted of a short-term bond fund and U.S. Treasuries. At December 31, 2017 short-term investments consisted of a short-term bond fund. Such investments are not insured by the Federal Deposit Insurance Corporation.</td> </tr> </table> Short-term bond fund The short-term bond fund is classified in trading securities. Trading securities are recorded at fair value based on the closing market price of the security. For trading securities, the Company recognizes realized gains and losses and unrealized gains and losses to earnings. At March 31, 2018 and December 31, 2017, the only investment classified as trading securities was the short-term bond fund. Unrealized gain (loss) for the three months ended March 31, 2018 and 2017 for trading securities was ($58,861) and $29,430, respectively, and is included in other income, net in the accompanying consolidated statements of operations. U.S. Treasuries U.S. Treasuries are classified as available-for sale-securities. The Company classifies available-for-sale securities with stated maturities of greater than three months from the date of purchase as short-term investments. At March 31, 2018, all U.S. Treasuries were due within one year. The Company records available-for-sale securities at fair value with unrealized gains and losses reported in accumulated other comprehensive income (loss) in stockholders’ equity. Realized gain and losses are included in other income, net and are derived using the specific identification method for determining the cost of securities sold. Interest income is recognized when earned and is included in other income, net in the consolidated statement of operations. The Company recognizes a charge when the declines in the fair value below the amortized cost basis of our available-for-sale securities are judged to be other-than-temporary. The Company considers various factors in determining whether to recognize an other-than-temporary charge, including whether the Company intends to sell the security or whether it is more likely than not that the Company would be required to sell the security before recovery of the amortized cost basis. The Company has not recorded any other than temporary impairment charges on its available-for-sale securities.   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="PAGE-BREAK-INSIDE: avoid"> <td width="8%"> </td> <td valign="top" width="9%" align="left">f.</td> <td valign="top" align="left">PREPAID EXPENSES AND OTHER CURRENT ASSETS. Prepaid expenses and other current assets consist primarily of prepaid research fees, prepaid pre-commercialization expenses, prepaid insurance and prepaid subscription fees. Prepaid research fees consist of advances for the Company’s product development activities, including drug manufacturing, contracts for pre-clinical studies, clinical trials and studies, regulatory affairs and consulting. Such advances are recorded as expense as the related goods are received or the related services are performed.</td> </tr> </table> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="PAGE-BREAK-INSIDE: avoid"> <td width="8%"> </td> <td valign="top" width="9%" align="left">g.</td> <td valign="top" align="left">FAIR VALUE OF FINANCIAL INSTRUMENTS. The Company’s financial instruments consist of cash and cash equivalents, short-term investments, accounts payables, accrued expenses and other liabilities, and warrants liability. At March 31, 2018 and December 31, 2017, the fair value of these instruments approximated their carrying value.</td> </tr> </table>   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="PAGE-BREAK-INSIDE: avoid"> <td width="8%"> </td> <td valign="top" width="9%" align="left">h.</td> <td valign="top" align="left">FAIR VALUE MEASUREMENTS. Current Financial Accounting Standards Board (FASB) fair value guidance emphasizes that fair value is a market-based measurement, not an entity-specific measurement. Therefore, a fair value measurement should be determined based on the assumptions that market participants would use in pricing the asset or liability. As a basis for considering market participant assumptions in fair value measurements, current FASB guidance establishes a fair value hierarchy that distinguishes between market participant assumptions based on market data obtained from sources independent of the reporting entity (observable inputs that are classified within Levels 1 and 2 of the hierarchy) and the reporting entity’s own assumptions that it believes market participants would use in pricing assets or liabilities (unobservable inputs classified within Level 3 of the hierarchy).</td> </tr> </table> Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. Level 2 inputs are inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs may include quoted prices for similar assets and liabilities in active markets, as well as inputs that are observable for the asset or liability (other than quoted prices), such as interest rates, foreign exchange rates, and yield curves that are observable at commonly quoted intervals. Level 3 inputs are unobservable inputs for the asset or liability, which are typically based on an entity’s own assumptions, as there is little, if any, related market activity. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and considers factors specific to the asset or liability.   <div align="right"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="83%" border="0"> <tr> <td width="54%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"> Fair Value Measurements at Reporting Date Using</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Balances as of March 31, 2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Quoted Prices in Active Markets for Identical Assets/Liabilities (Level 1)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Significant Other Observable Inputs (Level 2)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Significant Unobservable Inputs (Level 3)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Cash and cash equivalents: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Money market funds </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">19,343,497</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">19,343,497</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Short-term investments: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Short-term bond fund </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">26,496,992</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">26,496,992</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> U.S. Treasuries </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">31,845,586</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">31,845,586</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="16"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Balances as of December 31, 2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Quoted Prices in Active Markets for Identical Assets/Liabilities (Level 1)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Significant Other Observable Inputs (Level 2)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Significant Unobservable Inputs (Level 3)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Cash and cash equivalents: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Money market funds </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">56,820,688</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">56,820,688</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Short-term investments: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Short-term bond fund </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">26,516,711</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">26,516,711</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="PAGE-BREAK-INSIDE: avoid"> <td width="8%"> </td> <td valign="top" width="9%" align="left">i.</td> <td valign="top" align="left">WARRANTS LIABILITY. In October 2011, the Company issued 1,523,370 warrants (the 2011 warrants) to purchase shares of the Company’s common stock in connection with a registered direct offering. During the periods that the 2011 warrants were outstanding, the Company accounted for these warrants as a liability measured at fair value due to a provision included in the warrants agreement that provided the warrants holders with an option to require the Company (or its successor) to purchase their warrants for cash in an amount equal to their Black-Scholes Option Pricing Model (the Black-Scholes Model) value, in the event that certain fundamental transactions, as defined, occurred. The fair value of the warrants liability was estimated using the Black-Scholes Model which required inputs such as the expected term of the warrants, share price volatility and risk-free interest rate. These assumptions were reviewed on a quarterly basis and changes in the estimated fair value of the outstanding warrants were recognized each reporting period in the “Change in fair value of warrants liability” line in the consolidated statement of operations. At March 31, 2017, 763,913 of the 2011 warrants remained outstanding. All unexercised 2011 warrants expired on May 2, 2017. See Note 3.</td> </tr> </table>   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="PAGE-BREAK-INSIDE: avoid"> <td width="8%"> </td> <td valign="top" width="9%" align="left">j.</td> <td valign="top" align="left">STOCK-BASED COMPENSATION. The Company recognizes expense in the consolidated statement of operations for the fair value of all stock-based payments to employees, directors and consultants, including grants of stock options and other share-based awards. For stock options, the Company uses the Black-Scholes option valuation model, the single-option award approach, and the straight-line attribution method. Using this approach, compensation cost is amortized on a straight-line basis over the vesting period of each respective stock option, generally one to three years. Forfeitures are recognized as a reduction of share-based compensation expense as they occur.</td> </tr> </table> As of March 31, 2018, there were outstanding stock options to purchase 6,902,500 shares of common stock, of which stock options to purchase 3,616,662 shares of common stock were exercisable as of March 31, 2018. For the three-month periods ended March 31, 2018 and 2017, the Company recorded stock-based compensation expense as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="66%" align="center" border="0"> <tr> <td width="78%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"> Three months ended March 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Research and development </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">294,315</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">206,352</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> General and administrative </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">677,025</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">547,792</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Total stock-based compensation </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">971,340</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">754,144</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table>   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="PAGE-BREAK-INSIDE: avoid"> <td width="8%"> </td> <td valign="top" width="9%" align="left">k.</td> <td valign="top" align="left">COMPREHENSIVE INCOME (LOSS). U.S. GAAP require that all components of comprehensive income (loss) be reported in the financial statements in the period in which they are recognized. Comprehensive income (loss) is net income (loss), plus certain other items that are recorded directly into stockholders’ equity. The Company’s comprehensive loss is shown on the Consolidated Statement of Operations and Comprehensive Loss as of March 31, 2018 and is comprised of net unrealized losses on the Company’s available-for-sale securities. For December 31, 2017 and all prior periods, the Company’s net loss equaled comprehensive loss, since the Company had no items which were considered other comprehensive income (loss).</td> </tr> </table> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="PAGE-BREAK-INSIDE: avoid"> <td width="8%"> </td> <td valign="top" width="9%" align="left">l.</td> <td valign="top" align="left">NET LOSS PER SHARE. Basic loss per share is computed by dividing net loss for the period by the weighted average number of common shares outstanding during the period. The calculation of basic and diluted net loss per share is the same for all periods presented, as the effect of potential common stock equivalents is anti-dilutive due to the Company’s net loss position for all periods presented. The potential shares, which are excluded from the determination of basic and diluted net loss per share as their effect is anti-dilutive, are as follows:</td> </tr> </table>   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="66%" align="center" border="0"> <tr> <td width="76%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">March 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Options to purchase common stock </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,902,500</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,088,333</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Warrants to purchase common stock </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,407,663</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Unvested restricted stock </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">26,667</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Potential equivalent common stock excluded </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,902,500</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8,522,663</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> Potentially dilutive options to purchase common stock as of March 31, 2018 have exercise prices ranging from $0.79 to $4.64. Potentially dilutive options to purchase common stock as of March 31, 2017 had exercise prices ranging from $0.47 to $4.64.   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="PAGE-BREAK-INSIDE: avoid"> <td width="8%"> </td> <td valign="top" width="9%" align="left">m.</td> <td valign="top" align="left">RECENTLY ISSUED ACCOUNTING STANDARDS. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), which requires an entity to recognize assets and liabilities arising from a lease for both financing and operating leases. The ASU will also require new qualitative and quantitative disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, with early adoption permitted. The Company is currently evaluating the impact this accounting standard will have on its consolidated financial statements.</td> </tr> </table> In May 2017, the FASB issued ASU No. 2017-09, Compensation – Stock Compensation (Topic 718): Scope of Modification Accounting to clarify when to account for a change to the terms or conditions of a share-based payment award as a modification. Under this new guidance, modification accounting is required if the fair value, vesting conditions, or classification of the award changes as a result of the change in terms or conditions. ASU 2017-09 is effective for all entities for annual reporting periods beginning after December 15, 2017, including interim reporting periods within each annual reporting period, applied prospectively on or after the effective date. The Company adopted this standard in the first quarter of 2018. The adoption of this standard did not have a material impact on the Company’s consolidated financial statements.   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="PAGE-BREAK-INSIDE: avoid"> <td width="8%"> </td> <td valign="top" width="9%" align="left">n.</td> <td valign="top" align="left">RECLASSIFICATIONS. Certain prior year amounts in the consolidated financial statements have been reclassified to conform to the current year presentation.</td> </tr> </table> </div>

21826

<div> Short-term investments by security type were as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="59%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Amortized cost</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Gross Unrealized Gains</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Gross Unrealized Losses</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Estimated Fair Value</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> At March 31, 2018: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Short-term bond fund </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">26,555,853</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(58,861</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">26,496,992</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> U.S. Treasuries </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">31,867,412</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(21,826</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">31,845,586</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">58,423,265</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(80,687</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">58,342,578</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> At December 31, 2017: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Short-term bond fund </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">26,487,281</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">29,430</td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"></td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">26,516,711</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

80687

<div>b. <table> <tr> <td valign="top" align="left">PRINCIPLES OF CONSOLIDATION. The consolidated financial statements include the Company’s accounts and those of its wholly-owned subsidiary Catalyst Pharmaceuticals Ireland, Ltd. (“Catalyst Ireland”). All intercompany accounts and transactions have been eliminated in consolidation. Catalyst Ireland was organized in 2017.</td> </tr> </table> </div>

<div>d. <table> <tr> <td valign="top" align="left">CASH AND CASH EQUIVALENTS. The Company considers all highly liquid instruments purchased with an original maturity of three months or less to be cash equivalents. Cash equivalents consist mainly of money market funds. The Company has substantially all of its cash and cash equivalents deposited with one financial institution. These amounts at times may exceed federally insured limits.</td> </tr> </table> </div>

-37896111

-5721718

<div>k. <table> <tr> <td align="left" valign="top">COMPREHENSIVE INCOME (LOSS). U.S. GAAP require that all components of comprehensive income (loss) be reported in the financial statements in the period in which they are recognized. Comprehensive income (loss) is net income (loss), plus certain other items that are recorded directly into stockholders’ equity. The Company’s comprehensive loss is shown on the Consolidated Statement of Operations and Comprehensive Loss as of March 31, 2018 and is comprised of net unrealized losses on the Company’s available-for-sale securities. For December 31, 2017 and all prior periods, the Company’s net loss equaled comprehensive loss, since the Company had no items which were considered other comprehensive income (loss).</td> </tr> </table> </div>

--12-31

<div> Prepaid expenses and other current assets consist of the following:   <table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="66%"></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"> March 31, 2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"> December 31, 2017</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Prepaid research fees </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">249,094</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">388,977</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Prepaid insurance </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">501,181</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">638,139</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Prepaid pre-commercialization fees </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">76,900</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">65,000</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Prepaid subscription fees </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">92,916</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">23,347</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Prepaid rent </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">20,981</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td nowrap="nowrap" valign="bottom"> </td> <td nowrap="nowrap" valign="bottom" align="right"> —  </td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Other </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">51,756</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">58,281</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Total prepaid expenses and other current assets </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">992,828</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,173,744</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

8015

-0.06

Q1 2018 10-Q

2018-03-31 CATALYST PHARMACEUTICALS, INC. 0001369568

<div> The following table rolls forward the fair value of the Company’s warrants liability activity for the three-month period ended March 31, 2017:   <table cellspacing="0" cellpadding="0" width="68%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="78%"></td> <td valign="bottom" width="14%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"> Three months ended March 31, 2017</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Fair value, beginning of period </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">122,226</td> <td nowrap="nowrap" valign="bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Issuance of warrants </td> <td valign="bottom">  </td> <td nowrap="nowrap" valign="bottom"> </td> <td nowrap="nowrap" valign="bottom" align="right"> —  </td> <td nowrap="nowrap" valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Exercise of warrants </td> <td valign="bottom">  </td> <td nowrap="nowrap" valign="bottom"> </td> <td nowrap="nowrap" valign="bottom" align="right"> —  </td> <td nowrap="nowrap" valign="bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Change in fair value </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">397,235</td> <td nowrap="nowrap" valign="bottom"></td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Fair value, end of period </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">519,461</td> <td nowrap="nowrap" valign="bottom"></td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div>g. <table> <tr> <td align="left" valign="top">FAIR VALUE OF FINANCIAL INSTRUMENTS. The Company’s financial instruments consist of cash and cash equivalents, short-term investments, accounts payables, accrued expenses and other liabilities, and warrants liability. At March 31, 2018 and December 31, 2017, the fair value of these instruments approximated their carrying value.</td> </tr> </table> </div>

Accelerated Filer

2674398

-5699892

-1140552

-401277

-180916

-31847693

-6081450

5933440

33032

-5699892

-5933440

-21826

233548

31847693

<div>n. <table> <tr> <td valign="top" align="left">RECLASSIFICATIONS. Certain prior year amounts in the consolidated financial statements have been reclassified to conform to the current year presentation.</td> </tr> </table> </div>

<div> Property and equipment, net consists of the following:   <table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="66%"></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"> March 31, 2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"> December 31, 2017</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Computer equipment </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">27,915</td> <td nowrap="nowrap" valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">27,915</td> <td nowrap="nowrap" valign="bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Furniture and equipment </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">169,931</td> <td nowrap="nowrap" valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">169,931</td> <td nowrap="nowrap" valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Leasehold improvements </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">152,708</td> <td nowrap="nowrap" valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">152,708</td> <td nowrap="nowrap" valign="bottom"></td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">350,554</td> <td nowrap="nowrap" valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">350,554</td> <td nowrap="nowrap" valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Less: Accumulated depreciation </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(167,184</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(159,169</td> <td nowrap="nowrap" valign="bottom">) </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Total property and equipment, net </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">183,370</td> <td nowrap="nowrap" valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">191,385</td> <td nowrap="nowrap" valign="bottom"></td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

33032

3259042

<div> Accrued expenses and other liabilities consist of the following:   <table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="66%"></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"> March 31, 2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"> December 31, 2017</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Accrued preclinical and clinical trial expenses </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">990,080</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">970,649</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Accrued professional fees </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">558,260</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">227,457</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Accrued compensation and benefits </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">54,548</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">821,935</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Accrued license fees </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">278,750</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">252,500</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Deferred rent and lease incentive </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">25,597</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">24,011</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Other </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">19,136</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">24,035</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Current accrued expenses and other liabilities </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,926,371</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,320,587</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Deferred rent and lease incentive - non-current </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">150,395</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">157,456</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Non-current accrued expenses and other liabilities </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">150,395</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">157,456</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Total accrued expenses and other liabilities </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,076,766</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,478,043</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> For the three-month periods ended March 31, 2018 and 2017, the Company recorded stock-based compensation expense as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="66%" align="center" border="0"> <tr> <td width="78%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"> Three months ended March 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Research and development </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">294,315</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">206,352</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> General and administrative </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">677,025</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">547,792</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Total stock-based compensation </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">971,340</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">754,144</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and considers factors specific to the asset or liability.   <div align="right"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="83%" border="0"> <tr> <td width="54%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"> Fair Value Measurements at Reporting Date Using</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Balances as of March 31, 2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Quoted Prices in Active Markets for Identical Assets/Liabilities (Level 1)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Significant Other Observable Inputs (Level 2)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Significant Unobservable Inputs (Level 3)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Cash and cash equivalents: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Money market funds </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">19,343,497</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">19,343,497</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Short-term investments: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Short-term bond fund </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">26,496,992</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">26,496,992</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> U.S. Treasuries </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">31,845,586</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">31,845,586</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="16"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Balances as of December 31, 2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Quoted Prices in Active Markets for Identical Assets/Liabilities (Level 1)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Significant Other Observable Inputs (Level 2)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Significant Unobservable Inputs (Level 3)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Cash and cash equivalents: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Money market funds </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">56,820,688</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">56,820,688</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Short-term investments: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Short-term bond fund </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">26,516,711</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">26,516,711</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div> </div>

971340

0.79

4.64

33032

CPRX

102557350

<div>c. <table> <tr> <td valign="top" align="left">USE OF ESTIMATES. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.</td> </tr> </table> </div>

Three months <div> <table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr style="page-break-inside:avoid"> <td width="8%" valign="top" align="left">5.</td> <td align="left" valign="top">Prepaid Expenses and Other Current Assets.</td> </tr> </table> Prepaid expenses and other current assets consist of the following:   <table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="66%"></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"> March 31, 2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"> December 31, 2017</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Prepaid research fees </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">249,094</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">388,977</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Prepaid insurance </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">501,181</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">638,139</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Prepaid pre-commercialization fees </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">76,900</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">65,000</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Prepaid subscription fees </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">92,916</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">23,347</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Prepaid rent </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">20,981</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td nowrap="nowrap" valign="bottom"> </td> <td nowrap="nowrap" valign="bottom" align="right"> —  </td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Other </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">51,756</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">58,281</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Total prepaid expenses and other current assets </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">992,828</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,173,744</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div> <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="PAGE-BREAK-INSIDE: avoid"> <td width="8%"> </td> <td valign="top" width="9%" align="left">a.</td> <td valign="top" align="left">INTERIM FINANCIAL STATEMENTS. The accompanying unaudited interim consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP), and pursuant to the rules and regulations of the Securities and Exchange Commission (SEC) for reporting of interim financial information. Pursuant to such rules and regulations, certain information and note disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been omitted. The consolidated balance sheet as of December 31, 2017 included in this Form 10-Q was derived from the audited financial statements and does not include all disclosures required by U.S. GAAP.</td> </tr> </table> In the opinion of management, the accompanying unaudited interim consolidated financial statements of the Company contain all adjustments (consisting of only normal recurring adjustments) necessary to present fairly the financial position of the Company as of the dates and for the periods presented. Accordingly, these consolidated statements should be read in conjunction with the financial statements and notes thereto for the year ended December 31, 2017 included in the 2017 Annual Report on Form 10-K filed by the Company with the SEC. The results of operations for the three months ended March 31, 2018 are not necessarily indicative of the results to be expected for any future period or for the full 2018 fiscal year. </div> <div>i. <table> <tr> <td align="left" valign="top">WARRANTS LIABILITY. In October 2011, the Company issued 1,523,370 warrants (the 2011 warrants) to purchase shares of the Company’s common stock in connection with a registered direct offering. During the periods that the 2011 warrants were outstanding, the Company accounted for these warrants as a liability measured at fair value due to a provision included in the warrants agreement that provided the warrants holders with an option to require the Company (or its successor) to purchase their warrants for cash in an amount equal to their Black-Scholes Option Pricing Model (the Black-Scholes Model) value, in the event that certain fundamental transactions, as defined, occurred. The fair value of the warrants liability was estimated using the Black-Scholes Model which required inputs such as the expected term of the warrants, share price volatility and risk-free interest rate. These assumptions were reviewed on a quarterly basis and changes in the estimated fair value of the outstanding warrants were recognized each reporting period in the “Change in fair value of warrants liability” line in the consolidated statement of operations. At March 31, 2017, 763,913 of the 2011 warrants remained outstanding. All unexercised 2011 warrants expired on May 2, 2017. See Note 3.</td> </tr> </table> </div> <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="PAGE-BREAK-INSIDE: avoid"> <td valign="top" width="8%" align="left">3.</td> <td valign="top" align="left">Warrants Liability, at Fair Value.</td> </tr> </table> 2011 Warrants The Company allocated approximately $1.3 million of proceeds from its October 2011 registered direct offering to the fair value of common stock purchase warrants issued in connection with the offering that were classified as a liability (the 2011 warrants). The 2011 warrants were classified as a liability because of provisions in such warrants that allowed for the net cash settlement of such warrants in the event of certain fundamental transactions (as defined in the warrant agreement). During the period that the 2011 warrants were outstanding, the valuation of the 2011 warrants was determined using the Black-Scholes Model. This model uses inputs such as the underlying price of the shares issued when the warrant is exercised, volatility, risk free interest rate and expected life of the instrument. The Company had determined that the 2011 warrants liability should be classified within Level 3 of the fair value hierarchy by evaluating each input for the Black-Scholes Model against the fair value hierarchy criteria and using the lowest level of input as the basis for the fair value classification. There are six inputs: closing price of the Company’s common stock on the day of evaluation; the exercise price of the warrants; the remaining term of the warrants; the volatility of the Company’s common stock; annual rate of dividends; and the risk-free rate of return. Of those inputs, the exercise price of the warrants and the remaining term were readily observable in the warrants agreement. The annual rate of dividends was based on the Company’s historical practice of not granting dividends. The closing price of the Company’s common stock would fall under Level 1 of the fair value hierarchy as it is a quoted price in an active market. The risk-free rate of return was a Level 2 input, while the historical volatility was a Level 3 input in accordance with the fair value accounting guidance. Since the lowest level input was a Level 3, the Company determined the 2011 warrants liability were most appropriately classified within Level 3 of the fair value hierarchy. This liability was subject to a fair value mark-to-market adjustment each reporting period. All unexercised 2011 warrants expired on May 2, 2017. The calculated value of the 2011 warrants liability was determined using the Black-Scholes Model with the following assumptions:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="83%"></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">March 31, 2017</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Risk free interest rate </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.03</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Expected term </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.09 years</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Expected volatility </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">110</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Expected dividend yield </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Expected forfeiture rate </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> </table> The following table rolls forward the fair value of the Company’s warrants liability activity for the three-month period ended March 31, 2017:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="78%"></td> <td valign="bottom" width="14%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"> Three months ended March 31, 2017</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Fair value, beginning of period </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">122,226</td> <td valign="bottom" nowrap="nowrap"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Issuance of warrants </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Exercise of warrants </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Change in fair value </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">397,235</td> <td valign="bottom" nowrap="nowrap"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Fair value, end of period </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">519,461</td> <td valign="bottom" nowrap="nowrap"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> On May 2, 2017, the outstanding and unexercised 2011 warrants expired. During the three months ended March 31, 2017, none of the 2011 warrants were exercised. </div> <div>f. <table> <tr> <td valign="top" align="left">PREPAID EXPENSES AND OTHER CURRENT ASSETS. Prepaid expenses and other current assets consist primarily of prepaid research fees, prepaid pre-commercialization expenses, prepaid insurance and prepaid subscription fees. Prepaid research fees consist of advances for the Company’s product development activities, including drug manufacturing, contracts for pre-clinical studies, clinical trials and studies, regulatory affairs and consulting. Such advances are recorded as expense as the related goods are received or the related services are performed.</td> </tr> </table> </div> 1.00

971340

6902500

P2Y4M2D

33032

1772500

744998

36666

P7Y

P3Y

P1Y

<div> The calculated value of the 2011 warrants liability was determined using the Black-Scholes Model with the following assumptions:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="83%"></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">March 31, 2017</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Risk free interest rate </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.03</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Expected term </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.09 years</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Expected volatility </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">110</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Expected dividend yield </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Expected forfeiture rate </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> </table> </div>

2017-05-02 2017-05-02

-58861

677025

294315

21826

58861

150000 3000000 2425000 4200000 92500000

424885

P3Y 0.10 P1Y 0.07

971340

32995

-21826

-5699892

100000000 2012-10-26 P7Y 7200000 2600000 However, under BioMarin’s agreement with the former Huxley stockholders (and under the Company’s license agreement with BioMarin), BioMarin’s obligation to pay the milestone payments due to the former Huxley stockholders (and the Company’s corresponding obligation to pay such milestone payments) expired because the milestones were not satisfied by April 20, 2018.

8522663

-3912020

-4967129

12958

-0.06

397235

1865942

-4967129

-15248

-178917

-118082

-33145

-3878875

4679871

-4967129

-4679871

109977

33145

2813929

754144

0.47

4.64

82972316

26667

2407663

735536

6088333

1520000

255000

P7Y

P3Y

P1Y

18608

0.00

P0Y1M2D

1.10

0.0103

0.00 0

29430

547792

206352

0001369568 us-gaap:ResearchAndDevelopmentExpenseMember 2016-12-24 2017-03-31 0001369568 us-gaap:GeneralAndAdministrativeExpenseMember 2016-12-24 2017-03-31 0001369568 us-gaap:TradingAccountAssetsMember us-gaap:OtherIncomeMember 2016-12-24 2017-03-31 0001369568 us-gaap:WarrantMember cprx:OctoberTwentyEightTwoThousandAndElevenWarrantsMember 2016-12-24 2017-03-31 0001369568 us-gaap:WarrantMember 2016-12-24 2017-03-31 0001369568 us-gaap:RestrictedStockUnitsRSUMember 2016-12-24 2017-03-31 0001369568 cprx:OptionsToPurchaseCommonStockMember us-gaap:MinimumMember 2016-12-24 2017-03-31 0001369568 cprx:OptionsToPurchaseCommonStockMember us-gaap:MaximumMember 2016-12-24 2017-03-31 0001369568 cprx:OptionsToPurchaseCommonStockMember 2016-12-24 2017-03-31 0001369568 us-gaap:WarrantMember 2016-12-24 2017-03-31 0001369568 us-gaap:RestrictedStockMember 2016-12-24 2017-03-31 0001369568 2016-12-24 2017-03-31 0001369568 cprx:LicenseAgreementWithBioMarinMember 2018-01-01 2018-03-31 0001369568 us-gaap:RetainedEarningsMember 2018-01-01 2018-03-31 0001369568 us-gaap:CommonStockMember 2018-01-01 2018-03-31 0001369568 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-03-31 0001369568 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-03-31 0001369568 us-gaap:MinimumMember cprx:LicenseAgreementWithBioMarinMember 2018-01-01 2018-03-31 0001369568 us-gaap:MinimumMember 2018-01-01 2018-03-31 0001369568 us-gaap:MaximumMember cprx:LicenseAgreementWithBioMarinMember 2018-01-01 2018-03-31 0001369568 us-gaap:MaximumMember 2018-01-01 2018-03-31 0001369568 cprx:NorthwesternLicenseAgreementMember 2018-01-01 2018-03-31 0001369568 cprx:TwoThousandSeventeenShelfRegistrationStatementMember 2018-01-01 2018-03-31 0001369568 cprx:HuxleyMember cprx:LemsMember cprx:LicenseAgreementWithBioMarinMember 2018-01-01 2018-03-31 0001369568 cprx:HuxleyMember cprx:LemsOrCmsMember cprx:LicenseAgreementWithBioMarinMember 2018-01-01 2018-03-31 0001369568 cprx:ThirdPartyLicensorMember cprx:LemsMember cprx:LicenseAgreementWithBioMarinMember 2018-01-01 2018-03-31 0001369568 cprx:ThirdPartyLicensorMember cprx:LemsOrCmsMember cprx:LicenseAgreementWithBioMarinMember 2018-01-01 2018-03-31 0001369568 cprx:ShortTermBondFundMember 2018-01-01 2018-03-31 0001369568 us-gaap:USTreasurySecuritiesMember 2018-01-01 2018-03-31 0001369568 us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-03-31 0001369568 us-gaap:GeneralAndAdministrativeExpenseMember 2018-01-01 2018-03-31 0001369568 us-gaap:TradingAccountAssetsMember us-gaap:OtherIncomeMember 2018-01-01 2018-03-31 0001369568 us-gaap:WarrantMember cprx:OctoberTwentyEightTwoThousandAndElevenWarrantsMember 2018-01-01 2018-03-31 0001369568 us-gaap:WarrantMember 2018-01-01 2018-03-31 0001369568 us-gaap:RestrictedStockUnitsRSUMember 2018-01-01 2018-03-31 0001369568 cprx:OptionsToPurchaseCommonStockMember us-gaap:MinimumMember 2018-01-01 2018-03-31 0001369568 cprx:OptionsToPurchaseCommonStockMember us-gaap:MaximumMember 2018-01-01 2018-03-31 0001369568 cprx:OptionsToPurchaseCommonStockMember 2018-01-01 2018-03-31 0001369568 2018-01-01 2018-03-31 0001369568 cprx:ShortTermBondFundMember 2016-12-24 2017-12-31 0001369568 2016-12-24 2017-12-31 0001369568 cprx:OctoberTwentyEightTwoThousandAndElevenWarrantsMember 2011-10-01 2011-10-31 0001369568 us-gaap:WarrantMember cprx:OctoberTwentyEightTwoThousandAndElevenWarrantsMember 2011-10-01 2011-10-31 0001369568 cprx:UnderwrittenPublicOfferingMember 2017-11-28 2017-11-28 0001369568 us-gaap:RetainedEarningsMember 2017-12-31 0001369568 us-gaap:CommonStockMember 2017-12-31 0001369568 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001369568 us-gaap:LeaseholdImprovementsMember 2017-12-31 0001369568 us-gaap:FurnitureAndFixturesMember 2017-12-31 0001369568 us-gaap:ComputerEquipmentMember 2017-12-31 0001369568 cprx:ShortTermBondFundMember 2017-12-31 0001369568 us-gaap:FairValueInputsLevel1Member cprx:ShortTermBondFundMember 2017-12-31 0001369568 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2017-12-31 0001369568 us-gaap:MoneyMarketFundsMember 2017-12-31 0001369568 2017-12-31 0001369568 cprx:LicenseAgreementWithBioMarinMember 2018-03-31 0001369568 us-gaap:RetainedEarningsMember 2018-03-31 0001369568 us-gaap:CommonStockMember 2018-03-31 0001369568 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-03-31 0001369568 us-gaap:AdditionalPaidInCapitalMember 2018-03-31 0001369568 cprx:OctoberTwentyEightTwoThousandAndElevenWarrantsMember 2018-03-31 0001369568 cprx:NorthwesternLicenseAgreementMember 2018-03-31 0001369568 us-gaap:LeaseholdImprovementsMember 2018-03-31 0001369568 us-gaap:FurnitureAndFixturesMember 2018-03-31 0001369568 us-gaap:ComputerEquipmentMember 2018-03-31 0001369568 cprx:ShortTermBondFundMember 2018-03-31 0001369568 us-gaap:USTreasurySecuritiesMember 2018-03-31 0001369568 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasurySecuritiesMember 2018-03-31 0001369568 us-gaap:FairValueInputsLevel1Member cprx:ShortTermBondFundMember 2018-03-31 0001369568 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2018-03-31 0001369568 us-gaap:MoneyMarketFundsMember 2018-03-31 0001369568 cprx:OptionsToPurchaseCommonStockMember 2018-03-31 0001369568 2018-03-31 0001369568 2017-03-31 0001369568 cprx:TwoThousandSeventeenShelfRegistrationStatementMember 2017-07-12 0001369568 2018-05-04 0001369568 cprx:UnderwrittenPublicOfferingMember 2017-11-28 0001369568 cprx:TwoThousandSixteenShelfRegistrationStatementMember 2016-12-23 0001369568 2016-12-23 iso4217:USD iso4217:USD shares shares pure

EX-101.SCH 7 cprx-20180331.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 103 - Statement - Consolidated Balance Sheets link:calculationLink link:presentationLink link:definitionLink 104 - Statement - Consolidated Balance Sheets (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 105 - Statement - Consolidated Statements of Operations and Comprehensive Loss (unaudited) link:calculationLink link:presentationLink link:definitionLink 106 - Statement - Consolidated Statement of Stockholders' Equity (unaudited) link:calculationLink link:presentationLink link:definitionLink 107 - Statement - Consolidated Statements of Cash Flows (unaudited) link:calculationLink link:presentationLink link:definitionLink 108 - Disclosure - Organization and Description of Business link:calculationLink link:presentationLink link:definitionLink 109 - Disclosure - Basis of Presentation and Significant Accounting Policies link:calculationLink link:presentationLink link:definitionLink 110 - Disclosure - Warrants Liability, at Fair Value link:calculationLink link:presentationLink link:definitionLink 111 - Disclosure - Short-term Investments link:calculationLink link:presentationLink link:definitionLink 112 - Disclosure - Prepaid Expenses and Other Current Assets link:calculationLink link:presentationLink link:definitionLink 113 - Disclosure - Property and Equipment, net link:calculationLink link:presentationLink link:definitionLink 114 - Disclosure - Accrued Expenses and Other Liabilities link:calculationLink link:presentationLink link:definitionLink 115 - Disclosure - Commitments and Contingencies link:calculationLink link:presentationLink link:definitionLink 116 - Disclosure - Income Taxes link:calculationLink link:presentationLink link:definitionLink 117 - Disclosure - Stockholders' Equity link:calculationLink link:presentationLink link:definitionLink 118 - Disclosure - Stock Compensation link:calculationLink link:presentationLink link:definitionLink 119 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies) link:calculationLink link:presentationLink link:definitionLink 120 - Disclosure - Basis of Presentation and Significant Accounting Policies (Tables) link:calculationLink link:presentationLink link:definitionLink 121 - Disclosure - Warrants Liability, at Fair Value (Tables) link:calculationLink link:presentationLink link:definitionLink 122 - Disclosure - Short-term Investments (Tables) link:calculationLink link:presentationLink link:definitionLink 123 - Disclosure - Prepaid Expenses and Other Current Assets (Tables) link:calculationLink link:presentationLink link:definitionLink 124 - Disclosure - Property and Equipment, net (Tables) link:calculationLink link:presentationLink link:definitionLink 125 - Disclosure - Accrued Expenses and Other Liabilities (Tables) link:calculationLink link:presentationLink link:definitionLink 126 - Disclosure - Basis of Presentation and Significant Accounting Policies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 127 - Disclosure - Basis of Presentation and Significant Accounting Policies - Fair Value Measurement Specific to Assets or Liability (Detail) link:calculationLink link:presentationLink link:definitionLink 128 - Disclosure - Basis of Presentation and Significant Accounting Policies - Stock-Based Compensation Expense (Detail) link:calculationLink link:presentationLink link:definitionLink 129 - Disclosure - Basis of Presentation and Significant Accounting Policies - Potential Shares Excluded from Determination of Basic and Diluted Net Loss Per Share (Detail) link:calculationLink link:presentationLink link:definitionLink 130 - Disclosure - Warrants Liability, at Fair Value - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 131 - Disclosure - Warrants Liability, at Fair Value - Summary of Assumptions Used in Black-Scholes Model to Calculate Fair Value of Warrants Liability (Detail) link:calculationLink link:presentationLink link:definitionLink 132 - Disclosure - Warrants Liability, at Fair Value - Summary of Company's Warrants Liability Activity (Detail) link:calculationLink link:presentationLink link:definitionLink 133 - Disclosure - Short Term Investment - Summary of Short Term Investment by Security Type (Detail) link:calculationLink link:presentationLink link:definitionLink 134 - Disclosure - Short Term Investments - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 135 - Disclosure - Prepaid Expenses and Other Current Assets - Prepaid Expenses and Other Current Assets (Detail) link:calculationLink link:presentationLink link:definitionLink 136 - Disclosure - Property and Equipment, net - Property and Equipment, net (Detail) link:calculationLink link:presentationLink link:definitionLink 137 - Disclosure - Property and Equipment, net - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 138 - Disclosure - Accrued Expenses and Other Liabilities - Schedule of Accrued Expenses and Other Liabilities (Detail) link:calculationLink link:presentationLink link:definitionLink 139 - Disclosure - Commitments and Contingencies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 140 - Disclosure - Income Taxes - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 141 - Disclosure - Stockholders' Equity (2016 Shelf Registration Statement) - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 142 - Disclosure - Stockholders' Equity (2017 Shelf Registration Statement) - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 143 - Disclosure - Stock Compensation - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 8 cprx-20180331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 cprx-20180331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 cprx-20180331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Accounting Policies [Abstract] Accounting Policies [Abstract] Accounts Payable and Accrued Liabilities Disclosure [Text Block] Accrued Expenses and Other Liabilities Accounts Payable, Current Accounts payable Accrued Liabilities, Current Accrued expenses and other liabilities Current accrued expenses and other liabilities Accrued Liabilities Total accrued expenses and other liabilities Carrying value as of the balance sheet date of obligations incurred through that date and payable for license fees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Accrued License Fees Current Accrued license fees Carrying value as of the balance sheet date of obligations incurred through that date and payable pertaining to non clinical and clinical trial expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Accrued Non Clinical And Clinical Trial Expenses Accrued preclinical and clinical trial expenses Accrued Professional Fees, Current Accrued professional fees Accrued Rent, Noncurrent Deferred rent and lease incentive - non-current Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Less: Accumulated depreciation Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive loss AOCI Attributable to Parent [Member] Accumulated Other Comprehensive Loss [Member] Additional Paid in Capital Additional paid-in capital Additional Paid-in Capital [Member] Additional Paid-in Capital [Member] Adjustments to Additional Paid in Capital, Share-based Compensation, Stock Options, Requisite Service Period Recognition Issuance of stock options for services Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Allocated Share-based Compensation Expense Stock-based compensation Amendment Flag Amendment Flag Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Potential equivalent common stock excluded Antidilutive Securities [Axis] Antidilutive Securities [Axis] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Arrangements and Non-arrangement Transactions [Domain] Arrangements and Non-arrangement Transactions [Domain] Assets Total assets Assets [Abstract] ASSETS Assets, Current Total current assets Assets, Current [Abstract] Current Assets: Available-for-sale Securities Estimated Fair Value Available-for-sale Securities, Amortized Cost Basis Amortized cost Available-for-sale Securities, Gross Realized Gain (Loss) Realized gain losses from available for sale securities Available-for-sale Securities, Gross Unrealized Gain (Loss) Unrealized loss on available-for-sale securities Available-for-sale Securities, Gross Unrealized Gain Gross Unrealized Gains Available-for-sale Securities, Gross Unrealized Loss Gross Unrealized Losses Available-for-sale Securities [Table Text Block] Summary of Short Term Investment by Security type Award Type [Axis] Award Type [Axis] Basis of Presentation and Significant Accounting Policies [Text Block] Basis of Presentation and Significant Accounting Policies Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents - end of period Cash and cash equivalents - beginning of period Cash and cash equivalents Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Cash and Cash Equivalents, Fair Value Disclosure Money market funds Cash and Cash Equivalents, Period Increase (Decrease) Net increase (decrease) in cash and cash equivalents Cash and Cash Equivalents, Policy [Policy Text Block] CASH AND CASH EQUIVALENTS Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Non-cash investing activities: Number of warrants or rights issued. Class Of Warrant Or Right Issued Warrants issued in offering Class of Warrant or Right [Line Items] Class of Warrant or Right [Line Items] Class of Warrant or Right, Outstanding Warrants outstanding Class Of Warrant Or Rights Expiration Date Class Of Warrant Or Rights Expiration Date Warrants expiration date Class of Warrant or Right [Table] Class of Warrant or Right [Table] Commitments and Contingencies Commitments and contingencies Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Commitments. Commitments [Line Items] Commitments [Line Items] Potential amount to be paid upon milestone. Commitments Milestone Payments Potential Future milestone payment Commitments [Table] Commitments [Table] Commitments [Table] Common Stock [Member] Common Stock [Member] Common Stock, Par or Stated Value Per Share Common stock, par value Common Stock, Shares Authorized Common stock, shares authorized Value of common stock available for future sale. Common Stock Shares Available To Sell Under Agreement Value of common stock available for future sale Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Outstanding Common stock, shares outstanding Common Stock, Value, Issued Common stock, $0.001 par value, 150,000,000 shares authorized; 102,586,164 shares and 102,549,498 shares issued and outstanding at March 31, 2018 and December 31, 2017, respectively Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive loss Comprehensive Income, Policy [Policy Text Block] COMPREHENSIVE INCOME (LOSS) Computer Equipment [Member] Computer Equipment [Member] Consolidation, Policy [Policy Text Block] PRINCIPLES OF CONSOLIDATION Amount of costs paid in connection with product joint studies being conducted with licensor. Costs Paid for Product Joint Studies Costs paid for Firdapse joint studies Current Fiscal Year End Date Current Fiscal Year End Date Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block] Prepaid Expenses and Other Current Assets Deferred Rent Credit, Current Deferred rent and lease incentive Deferred tax assets valuation allowance percentage. Deferred Tax Assets Valuation Allowance Percentage Valuation allowance Deposits Assets, Noncurrent Deposits Depreciation Depreciation Depreciation expenses Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Stock Compensation Document and entity information. Document And Entity Information [Abstract] Document And Entity Information [Abstract] Document Fiscal Period Focus Document Fiscal Period Focus Document Fiscal Year Focus Document Fiscal Year Focus Document Period End Date Document Period End Date Document Type Document Type Earnings Per Share, Basic and Diluted Net loss per share - basic and diluted Earnings Per Share, Policy [Policy Text Block] NET LOSS PER SHARE Employee-related Liabilities, Current Accrued compensation and benefits Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized Unrecognized compensation expense related to non-vested stock compensation awards granted under the Plan Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Expected remaining weighted average vesting period Entity Central Index Key Entity Central Index Key Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity [Domain] Entity [Domain] Entity Filer Category Entity Filer Category Entity Registrant Name Entity Registrant Name Equity [Abstract] Equity [Abstract] Equity Component [Domain] Equity Component [Domain] Fair Value Adjustment of Warrants Change in fair value of warrants liability Change in fair value of warrants liability Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block] Summary of Assumptions Used in Black-Scholes Model to Calculate Fair Value of Warrants Liability Fair Value Assumptions, Expected Dividend Rate Expected dividend yield Expected forfeiture rate assumption used in valuing an instrument. Fair Value Assumptions Expected Forfeiture Rate Expected forfeiture rate Fair Value Assumptions, Expected Term Expected term Fair Value Assumptions, Expected Volatility Rate Expected volatility Fair Value Assumptions, Risk Free Interest Rate Risk free interest rate Fair Value, Hierarchy [Axis] Fair Value, Hierarchy [Axis] Fair Value by Shareholders' Equity Class [Domain] Fair Value by Shareholders' Equity Class [Domain] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Fair Value, Inputs, Level 1 [Member] Quoted Prices in Active Markets for Identical Assets/Liabilities (Level 1) [Member] Fair Value, Inputs, Level 2 [Member] Significant Other Observable Inputs (Level 2) [Member] Fair Value Inputs, Liabilities, Quantitative Information [Line Items] Fair Value Inputs, Liabilities, Quantitative Information [Line Items] Fair Value Inputs, Liabilities, Quantitative Information [Table] Fair Value Inputs, Liabilities, Quantitative Information [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Summary of Company's Warrants Liability Activity Fair Value Measurement, Policy [Policy Text Block] FAIR VALUE MEASUREMENTS Fair Value Hierarchy [Domain] Fair Value Hierarchy [Domain] Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances Issuance of warrants Recognition of warrants fair value at date of issuance Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) Change in fair value Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements Exercise of warrants Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value Fair value, end of period Fair value, beginning of period Fair Value of Financial Instruments, Policy [Policy Text Block] FAIR VALUE OF FINANCIAL INSTRUMENTS Financial Instrument [Axis] Financial Instrument [Axis] Furniture and Fixtures [Member] Furniture and Equipment [Member] Gain (Loss) on Investments Unrealized gain (loss) Investments by Category [Axis] Investments by Category [Axis] Marketable Securities and Investments Held at Cost [Domain] Marketable Securities and Investments Held at Cost [Domain] General and Administrative Expense General and administrative General and Administrative Expense [Member] General and Administrative [Member] Huxley. Huxley [Member] Huxley [Member] Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Loss before income taxes Income Statement [Abstract] Income Statement [Abstract] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Income Tax Disclosure [Text Block] Income Taxes Income Tax Expense (Benefit) Provision for income taxes Increase (Decrease) in Accounts Payable Accounts payable Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Accrued expenses and other liabilities Increase (Decrease) in Operating Assets [Abstract] (Increase) decrease in: Increase (Decrease) in Operating Liabilities [Abstract] Increase (decrease) in: Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other current assets and deposits Disclosure of accounting policy for interim financial statements. Interim Financial Statements Policy [Text Block] INTERIM FINANCIAL STATEMENTS Investment, Policy [Policy Text Block] SHORT-TERM INVESTMENTS Investments, Debt and Equity Securities [Abstract] Investments, Debt and Equity Securities [Abstract] Investments, Fair Value Disclosure Investments Fair Value Disclosure Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Short-term Investments Investment Type [Axis] Investment Type [Axis] Investments [Domain] Investments [Domain] Investment Warrants Expiration Date Warrants expiration date Leasehold Improvements [Member] Leasehold Improvements [Member] Legal Entity [Axis] Legal Entity [Axis] Lems. Lems [Member] Lems [Member] Lems or Cms. Lems or Cms [Member] Lems or Cms [Member] Liabilities Total liabilities Liabilities and Equity Total liabilities and stockholders' equity Liabilities and Equity [Abstract] LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities, Current Total current liabilities Liabilities, Current [Abstract] Current Liabilities: License agreement with BioMarin. License Agreement With Bio Marin [Member] License Agreement with BioMarin [Member] License Costs License fee paid Maximum dollar amount of common stock to be issued under shelf registration statement. Maximum Amount Of Common Stock That Can Be Issued Under Shelf Registration Statement Maximum dollar amount of common stock to be issued under shelf registration statement Maximum amount of securities that can be issued under shelf registration statement. Maximum Amount of Securities that can be Issued under Shelf Registration Statement Maximum dollar amount of securities to be issued under shelf registration statement Maximum length of time to maturity for instruments included as cash equivalents. Maximum Maturity Period Of Cash And Cash Equivalent Maximum maturity period of cash and cash equivalent Maximum [Member] Maximum [Member] Maximum amount of milestone payment that will be due upon the acceptance of a New Drug Application by the FDA. Maximum Milestone Payment Due Upon New Drug Applications Acceptance Milestone payment due upon NDA acceptance Maximum amount of milestone payment that will be due upon the approval of a New Drug Application by the FDA. Maximum Milestone Payment Due Upon New Drug Applications Approval Milestone payment due upon NDA approval Milestone payment description. Milestone Payment Description Milestone Payment Description Amount of milestone payment that will be due upon the acceptance of a New Drug Application by the FDA. Milestone Payment Due Upon New Drug Applications Acceptance Milestone payment due upon new drug application acceptance Amount of milestone payment that will be due upon approval of a New Drug Application by the FDA. Milestone Payment Due Upon New Drug Applications Approval Milestone payment due upon new drug application approval Minimum amount of time in which compensation cost from stock options is amortized on a straight line basis. Minimum Amortization Period Of Compensation Cost On Straight Line Basis Minimum amortization period of compensation cost on straight line basis Minimum [Member] Minimum [Member] Money Market Funds [Member] Money Market Funds [Member] Nature of Operations [Text Block] Organization and Description of Business Net Cash Provided by (Used in) Financing Activities, Continuing Operations Net cash provided by (used in) financing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Financing Activities: Net Cash Provided by (Used in) Investing Activities, Continuing Operations Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Investing Activities: Net Cash Provided by (Used in) Operating Activities, Continuing Operations Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Operating Activities: Net Income (Loss) Attributable to Parent Net loss Net loss Represents the amount used to determine the percentage of royalties for the period from the first commercial sale equal to the minimum percentage of net sales in North America for any calendar year for sales up to the amount, and maximum percentage of net sales in North America in any calendar year in excess of the amount. Net Sales Royalty Threshold Net sales royalty threshold New Accounting Pronouncements, Policy [Policy Text Block] RECENTLY ISSUED ACCOUNTING STANDARDS Northwestern license agreement. Northwestern License Agreement [Member] Northwestern License Agreement [Member] Number of warrants exercised during period. Number Of Warrants Exercised Number of warrants exercised during the period Warrants issued on October twenty eight, two thousand eleven. October Twenty Eight Two Thousand And Eleven Warrants [Member] October 28, 2011 Warrants [Member] Operating Costs and Expenses [Abstract] Operating costs and expenses: Operating Expenses Total operating costs and expenses Operating Income (Loss) Loss from operations Options to purchase common stock. Options To Purchase Common Stock [Member] Options to Purchase Common Stock [Member] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Other Accrued Liabilities, Current Other Other Accrued Liabilities, Noncurrent Accrued expenses and other liabilities, non-current Non-current accrued expenses and other liabilities Other Comprehensive Income (Loss), Net of Tax Other comprehensive loss Other Comprehensive Income (Loss), Net of Tax [Abstract] Other comprehensive loss: Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax Unrealized gain (loss) on available-for-sale securities Other Income [Member] Other Income, Net [Member] Other Nonoperating Income (Expense) Other income, net Other Prepaid Expense, Current Other Payables and Accruals [Abstract] Payables and Accruals [Abstract] EX-101.PRE 11 cprx-20180331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2018	May 04, 2018
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	Q1
Trading Symbol	CPRX
Entity Registrant Name	CATALYST PHARMACEUTICALS, INC.
Entity Central Index Key	0001369568
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		102,596,164

XML 13 R2.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Current Assets:
Cash and cash equivalents	$ 19,600,591	$ 57,496,702
Short-term investments	58,342,578	26,516,711
Prepaid expenses and other current assets	992,828	1,173,744
Total current assets	78,935,997	85,187,157
Property and equipment, net	183,370	191,385
Deposits	8,888	8,888
Total assets	79,128,255	85,387,430
Current Liabilities:
Accounts payable	805,023	1,945,575
Accrued expenses and other liabilities	1,926,371	2,320,587
Total current liabilities	2,731,394	4,266,162
Accrued expenses and other liabilities, non-current	150,395	157,456
Total liabilities	2,881,789	4,423,618
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.001 par value, 5,000,000 shares authorized: none issued and outstanding at March 31, 2018 and December 31, 2017
Common stock, $0.001 par value, 150,000,000 shares authorized; 102,586,164 shares and 102,549,498 shares issued and outstanding at March 31, 2018 and December 31, 2017, respectively	102,586	102,549
Additional paid-in capital	208,426,045	207,421,710
Accumulated deficit	(132,260,339)	(126,560,447)
Accumulated other comprehensive loss	(21,826)
Total stockholders' equity	76,246,466	80,963,812
Total liabilities and stockholders' equity	$ 79,128,255	$ 85,387,430

XML 14 R3.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2018	Dec. 31, 2017
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	102,586,164	102,549,498
Common stock, shares outstanding	102,586,164	102,549,498

XML 15 R4.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Operations and Comprehensive Loss (unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Operating costs and expenses:
Research and development	$ 3,259,042	$ 2,813,929
General and administrative	2,674,398	1,865,942
Total operating costs and expenses	5,933,440	4,679,871
Loss from operations	(5,933,440)	(4,679,871)
Other income, net	233,548	109,977
Change in fair value of warrants liability		(397,235)
Loss before income taxes	(5,699,892)	(4,967,129)
Provision for income taxes	0	0
Net loss	$ (5,699,892)	$ (4,967,129)
Net loss per share - basic and diluted	$ (0.06)	$ (0.06)
Weighted average shares outstanding - basic and diluted	102,557,350	82,972,316
Other comprehensive loss:
Unrealized gain (loss) on available-for-sale securities	$ (21,826)
Comprehensive loss	$ (5,721,718)	$ (4,967,129)

XML 16 R5.htm IDEA: XBRL DOCUMENT

Consolidated Statement of Stockholders' Equity (unaudited) - 3 months ended Mar. 31, 2018 - USD ($)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Loss [Member]
Beginning Balance at Dec. 31, 2017	$ 80,963,812	$ 102,549	$ 207,421,710	$ (126,560,447)
Issuance of stock options for services	971,340		971,340
Exercise of stock options for common stock	33,032	37	32,995
Other comprehensive loss	(21,826)				$ (21,826)
Net loss	(5,699,892)			(5,699,892)
Ending Balance at Mar. 31, 2018	$ 76,246,466	$ 102,586	$ 208,426,045	$ (132,260,339)	$ (21,826)

XML 17 R6.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Cash Flows (unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Operating Activities:
Net loss	$ (5,699,892)	$ (4,967,129)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	8,015	12,958
Stock-based compensation	971,340	754,144
Change in fair value of warrants liability		397,235
(Increase) decrease in:
Prepaid expenses and other current assets and deposits	180,916	118,082
Increase (decrease) in:
Accounts payable	(1,140,552)	(15,248)
Accrued expenses and other liabilities	(401,277)	(178,917)
Net cash used in operating activities	(6,081,450)	(3,878,875)
Investing Activities:
Purchase of investments	(31,847,693)	(33,145)
Net cash provided by (used in) investing activities	(31,847,693)	(33,145)
Financing Activities:
Proceeds from exercise of stock options	33,032
Net cash provided by (used in) financing activities	33,032
Net increase (decrease) in cash and cash equivalents	(37,896,111)	(3,912,020)
Cash and cash equivalents - beginning of period	57,496,702	13,893,064
Cash and cash equivalents - end of period	19,600,591	$ 9,981,044
Non-cash investing activities:
Unrealized loss on available-for-sale securities	$ 21,826

XML 18 R7.htm IDEA: XBRL DOCUMENT

Organization and Description of Business

3 Months Ended

Mar. 31, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Organization and Description of Business

1.	Organization and Description of Business.

Capital Resources

While there can be no assurance, based on currently available information, the Company estimates that it has sufficient resources to support its operations for at least the next 12 months.

XML 19 R8.htm IDEA: XBRL DOCUMENT

Basis of Presentation and Significant Accounting Policies

3 Months Ended

Mar. 31, 2018

Accounting Policies [Abstract]

Basis of Presentation and Significant Accounting Policies

2.	Basis of Presentation and Significant Accounting Policies.

Short-term bond fund

U.S. Treasuries


	Fair Value Measurements at Reporting Date Using
	Balances as of March 31, 2018		Quoted Prices in Active Markets for Identical Assets/Liabilities (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Cash and cash equivalents:
Money market funds	$	19,343,497	$	19,343,497	$	—	$	—

Short-term investments:
Short-term bond fund	$	26,496,992	$	26,496,992	$	—	$	—

U.S. Treasuries	$	31,845,586	$	—	$	31,845,586	$	—


	Balances as of December 31, 2017		Quoted Prices in Active Markets for Identical Assets/Liabilities (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Cash and cash equivalents:
Money market funds	$	56,820,688	$	56,820,688	$	—	$	—

Short-term investments:
Short-term bond fund	$	26,516,711	$	26,516,711	$	—	$	—

For the three-month periods ended March 31, 2018 and 2017, the Company recorded stock-based compensation expense as follows:


	Three months ended March 31,
	2018		2017
Research and development	$	294,315	$	206,352
General and administrative		677,025		547,792

Total stock-based compensation	$	971,340	$	754,144


	March 31,
	2018		2017
Options to purchase common stock		6,902,500		6,088,333
Warrants to purchase common stock		—		2,407,663
Unvested restricted stock		—		26,667

Potential equivalent common stock excluded		6,902,500		8,522,663

RECLASSIFICATIONS. Certain prior year amounts in the consolidated financial statements have been reclassified to conform to the current year presentation.

XML 20 R9.htm IDEA: XBRL DOCUMENT

Warrants Liability, at Fair Value

3 Months Ended

Mar. 31, 2018

Text Block [Abstract]

Warrants Liability, at Fair Value

3.	Warrants Liability, at Fair Value.

2011 Warrants

The calculated value of the 2011 warrants liability was determined using the Black-Scholes Model with the following assumptions:


	March 31, 2017
Risk free interest rate		1.03	%
Expected term		0.09 years
Expected volatility		110	%
Expected dividend yield		0	%
Expected forfeiture rate		0	%

The following table rolls forward the fair value of the Company’s warrants liability activity for the three-month period ended March 31, 2017:


	Three months ended March 31, 2017
Fair value, beginning of period	$	122,226
Issuance of warrants		—
Exercise of warrants		—
Change in fair value		397,235

Fair value, end of period	$	519,461

On May 2, 2017, the outstanding and unexercised 2011 warrants expired. During the three months ended March 31, 2017, none of the 2011 warrants were exercised.

XML 21 R10.htm IDEA: XBRL DOCUMENT

Short-term Investments

3 Months Ended

Mar. 31, 2018

Investments, Debt and Equity Securities [Abstract]

Short-term Investments

4.	Short-term Investments.

Short-term investments by security type were as follows:


	Amortized cost		Gross Unrealized Gains		Gross Unrealized Losses			Estimated Fair Value
At March 31, 2018:
Short-term bond fund	$	26,555,853	$	—	$	(58,861	)	$	26,496,992
U.S. Treasuries		31,867,412		—		(21,826	)		31,845,586

Total	$	58,423,265	$	—	$	(80,687	)	$	58,342,578

At December 31, 2017:
Short-term bond fund	$	26,487,281	$	29,430	$	—		$	26,516,711

Certain U.S. Treasuries at March 31, 2018 had fair valued less than their amortized costs and, therefore, contained unrealized losses. Given that the Company has no intent to sell the U.S. Treasuries until a recovery of its fair value, which may be at maturity, and there are no current requirements to sell any of these securities, the Company did not consider these investments to be other-than-temporarily impaired as of March 31, 2018. The Company anticipates full recovery of amortized costs with respect to these investments at maturity. The duration of time the U.S. Treasuries have been in a continuous unrealized loss position as of March 31, 2018 was less than 3 months.

XML 22 R11.htm IDEA: XBRL DOCUMENT

Prepaid Expenses and Other Current Assets

3 Months Ended

Mar. 31, 2018

Text Block [Abstract]

Prepaid Expenses and Other Current Assets

5.	Prepaid Expenses and Other Current Assets.

Prepaid expenses and other current assets consist of the following:


	March 31, 2018		December 31, 2017
Prepaid research fees	$	249,094	$	388,977
Prepaid insurance		501,181		638,139
Prepaid pre-commercialization fees		76,900		65,000
Prepaid subscription fees		92,916		23,347
Prepaid rent		20,981		—
Other		51,756		58,281

Total prepaid expenses and other current assets	$	992,828	$	1,173,744

XML 23 R12.htm IDEA: XBRL DOCUMENT

Property and Equipment, net

3 Months Ended

Mar. 31, 2018

Property, Plant and Equipment [Abstract]

Property and Equipment, net

6.	Property and Equipment, net.

Property and equipment, net consists of the following:


	March 31, 2018			December 31, 2017
Computer equipment	$	27,915		$	27,915
Furniture and equipment		169,931			169,931
Leasehold improvements		152,708			152,708

		350,554			350,554
Less: Accumulated depreciation		(167,184	)		(159,169	)

Total property and equipment, net	$	183,370		$	191,385

Depreciation expense was $8,015 and $12,958, respectively, for the three-month periods ended March 31, 2018 and 2017 respectively.

XML 24 R13.htm IDEA: XBRL DOCUMENT

Accrued Expenses and Other Liabilities

3 Months Ended

Mar. 31, 2018

Payables and Accruals [Abstract]

Accrued Expenses and Other Liabilities

7.	Accrued Expenses and Other Liabilities.

Accrued expenses and other liabilities consist of the following:


	March 31, 2018		December 31, 2017
Accrued preclinical and clinical trial expenses	$	990,080	$	970,649
Accrued professional fees		558,260		227,457
Accrued compensation and benefits		54,548		821,935
Accrued license fees		278,750		252,500
Deferred rent and lease incentive		25,597		24,011
Other		19,136		24,035

Current accrued expenses and other liabilities		1,926,371		2,320,587

Deferred rent and lease incentive - non-current		150,395		157,456

Non-current accrued expenses and other liabilities		150,395		157,456

Total accrued expenses and other liabilities	$	2,076,766	$	2,478,043

XML 25 R14.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

3 Months Ended

Mar. 31, 2018

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

8.	Commitments and Contingencies.

LICENSE AGREEMENT WITH BIOMARIN. On October 26, 2012, the Company entered into a license agreement with BioMarin Pharmaceutical, Inc. (BioMarin) for the North American rights to Firdapse^®.

XML 26 R15.htm IDEA: XBRL DOCUMENT

Income Taxes

3 Months Ended

Mar. 31, 2018

Income Tax Disclosure [Abstract]

Income Taxes

9.	Income Taxes.

XML 27 R16.htm IDEA: XBRL DOCUMENT

Stockholders' Equity

3 Months Ended

Mar. 31, 2018

Equity [Abstract]

Stockholders' Equity

10.

Stockholders’ Equity.

2016 Shelf Registration Statement

2017 Shelf Registration Statement

(a)

As of March 31, 2018, there is approximately $92.5 million available for future sale under the 2017 Shelf Registration Statement.

XML 28 R17.htm IDEA: XBRL DOCUMENT

Stock Compensation

3 Months Ended

Mar. 31, 2018

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Stock Compensation

11.

Stock Compensation.

Stock Options

Restricted Stock Units

XML 29 R18.htm IDEA: XBRL DOCUMENT

Basis of Presentation and Significant Accounting Policies (Policies)

3 Months Ended

Mar. 31, 2018

Accounting Policies [Abstract]

INTERIM FINANCIAL STATEMENTS

PRINCIPLES OF CONSOLIDATION

USE OF ESTIMATES

CASH AND CASH EQUIVALENTS

SHORT-TERM INVESTMENTS

Short-term bond fund

U.S. Treasuries

PREPAID EXPENSES AND OTHER CURRENT ASSETS

FAIR VALUE OF FINANCIAL INSTRUMENTS

FAIR VALUE MEASUREMENTS


	Fair Value Measurements at Reporting Date Using
	Balances as of March 31, 2018		Quoted Prices in Active Markets for Identical Assets/Liabilities (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Cash and cash equivalents:
Money market funds	$	19,343,497	$	19,343,497	$	—	$	—

Short-term investments:
Short-term bond fund	$	26,496,992	$	26,496,992	$	—	$	—

U.S. Treasuries	$	31,845,586	$	—	$	31,845,586	$	—


	Balances as of December 31, 2017		Quoted Prices in Active Markets for Identical Assets/Liabilities (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Cash and cash equivalents:
Money market funds	$	56,820,688	$	56,820,688	$	—	$	—

Short-term investments:
Short-term bond fund	$	26,516,711	$	26,516,711	$	—	$	—

WARRANTS LIABILITY

STOCK-BASED COMPENSATION

For the three-month periods ended March 31, 2018 and 2017, the Company recorded stock-based compensation expense as follows:


	Three months ended March 31,
	2018		2017
Research and development	$	294,315	$	206,352
General and administrative		677,025		547,792

Total stock-based compensation	$	971,340	$	754,144

COMPREHENSIVE INCOME (LOSS)

NET LOSS PER SHARE


	March 31,
	2018		2017
Options to purchase common stock		6,902,500		6,088,333
Warrants to purchase common stock		—		2,407,663
Unvested restricted stock		—		26,667

Potential equivalent common stock excluded		6,902,500		8,522,663

RECENTLY ISSUED ACCOUNTING STANDARDS

RECLASSIFICATIONS

RECLASSIFICATIONS. Certain prior year amounts in the consolidated financial statements have been reclassified to conform to the current year presentation.

XML 30 R19.htm IDEA: XBRL DOCUMENT

Basis of Presentation and Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2018

Accounting Policies [Abstract]

Fair Value Measurement Specific to Assets or Liability

The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and considers factors specific to the asset or liability.


	Fair Value Measurements at Reporting Date Using
	Balances as of March 31, 2018		Quoted Prices in Active Markets for Identical Assets/Liabilities (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Cash and cash equivalents:
Money market funds	$	19,343,497	$	19,343,497	$	—	$	—

Short-term investments:
Short-term bond fund	$	26,496,992	$	26,496,992	$	—	$	—

U.S. Treasuries	$	31,845,586	$	—	$	31,845,586	$	—


	Balances as of December 31, 2017		Quoted Prices in Active Markets for Identical Assets/Liabilities (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Cash and cash equivalents:
Money market funds	$	56,820,688	$	56,820,688	$	—	$	—

Short-term investments:
Short-term bond fund	$	26,516,711	$	26,516,711	$	—	$	—

Stock-Based Compensation Expense

For the three-month periods ended March 31, 2018 and 2017, the Company recorded stock-based compensation expense as follows:


	Three months ended March 31,
	2018		2017
Research and development	$	294,315	$	206,352
General and administrative		677,025		547,792

Total stock-based compensation	$	971,340	$	754,144

Potential Shares Excluded from Determination of Basic and Diluted Net Loss Per Share


	March 31,
	2018		2017
Options to purchase common stock		6,902,500		6,088,333
Warrants to purchase common stock		—		2,407,663
Unvested restricted stock		—		26,667

Potential equivalent common stock excluded		6,902,500		8,522,663

XML 31 R20.htm IDEA: XBRL DOCUMENT

Warrants Liability, at Fair Value (Tables)

3 Months Ended

Mar. 31, 2018

Summary of Company's Warrants Liability Activity

The following table rolls forward the fair value of the Company’s warrants liability activity for the three-month period ended March 31, 2017:


	Three months ended March 31, 2017
Fair value, beginning of period	$	122,226
Issuance of warrants		—
Exercise of warrants		—
Change in fair value		397,235

Fair value, end of period	$	519,461

Warrants Liability, at Fair Value [Member]

Summary of Assumptions Used in Black-Scholes Model to Calculate Fair Value of Warrants Liability

The calculated value of the 2011 warrants liability was determined using the Black-Scholes Model with the following assumptions:


	March 31, 2017
Risk free interest rate		1.03	%
Expected term		0.09 years
Expected volatility		110	%
Expected dividend yield		0	%
Expected forfeiture rate		0	%

XML 32 R21.htm IDEA: XBRL DOCUMENT

Short-term Investments (Tables)

3 Months Ended

Mar. 31, 2018

Investments, Debt and Equity Securities [Abstract]

Summary of Short Term Investment by Security type

Short-term investments by security type were as follows:


	Amortized cost		Gross Unrealized Gains		Gross Unrealized Losses			Estimated Fair Value
At March 31, 2018:
Short-term bond fund	$	26,555,853	$	—	$	(58,861	)	$	26,496,992
U.S. Treasuries		31,867,412		—		(21,826	)		31,845,586

Total	$	58,423,265	$	—	$	(80,687	)	$	58,342,578

At December 31, 2017:
Short-term bond fund	$	26,487,281	$	29,430	$	—		$	26,516,711

- Definition

Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.

+ References + Details

XML 33 R22.htm IDEA: XBRL DOCUMENT

Prepaid Expenses and Other Current Assets (Tables)

3 Months Ended

Mar. 31, 2018

Text Block [Abstract]

Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consist of the following:


	March 31, 2018		December 31, 2017
Prepaid research fees	$	249,094	$	388,977
Prepaid insurance		501,181		638,139
Prepaid pre-commercialization fees		76,900		65,000
Prepaid subscription fees		92,916		23,347
Prepaid rent		20,981		—
Other		51,756		58,281

Total prepaid expenses and other current assets	$	992,828	$	1,173,744

XML 34 R23.htm IDEA: XBRL DOCUMENT

Property and Equipment, net (Tables)

3 Months Ended

Mar. 31, 2018

Property, Plant and Equipment [Abstract]

Property and Equipment, net

Property and equipment, net consists of the following:


	March 31, 2018			December 31, 2017
Computer equipment	$	27,915		$	27,915
Furniture and equipment		169,931			169,931
Leasehold improvements		152,708			152,708

		350,554			350,554
Less: Accumulated depreciation		(167,184	)		(159,169	)

Total property and equipment, net	$	183,370		$	191,385

XML 35 R24.htm IDEA: XBRL DOCUMENT

Accrued Expenses and Other Liabilities (Tables)

3 Months Ended

Mar. 31, 2018

Payables and Accruals [Abstract]

Schedule of Accrued Expenses and Other Liabilities

Accrued expenses and other liabilities consist of the following:


	March 31, 2018		December 31, 2017
Accrued preclinical and clinical trial expenses	$	990,080	$	970,649
Accrued professional fees		558,260		227,457
Accrued compensation and benefits		54,548		821,935
Accrued license fees		278,750		252,500
Deferred rent and lease incentive		25,597		24,011
Other		19,136		24,035

Current accrued expenses and other liabilities		1,926,371		2,320,587

Deferred rent and lease incentive - non-current		150,395		157,456

Non-current accrued expenses and other liabilities		150,395		157,456

Total accrued expenses and other liabilities	$	2,076,766	$	2,478,043

XML 36 R25.htm IDEA: XBRL DOCUMENT

Basis of Presentation and Significant Accounting Policies - Additional Information (Detail) - USD ($)	1 Months Ended	3 Months Ended
	Oct. 31, 2011	Mar. 31, 2018	Mar. 31, 2017
Summary Of Basis Of Presentation And Significant Accounting Policies [Line Items]
Maximum maturity period of cash and cash equivalent		Three months
Number of options outstanding		6,902,500
Number of options exercisable		3,616,662
Stock option exercise price range, Minimum		$ 0.79	$ 0.47
Stock option exercise price range, Maximum		$ 4.64	$ 4.64
October 28, 2011 Warrants [Member]
Summary Of Basis Of Presentation And Significant Accounting Policies [Line Items]
Warrants issued in offering	1,523,370
Warrants outstanding		763,913
October 28, 2011 Warrants [Member] \| Warrants Liability, at Fair Value [Member]
Summary Of Basis Of Presentation And Significant Accounting Policies [Line Items]
Warrants expiration date		May 02, 2017
Trading Securities [Member] \| Other Income, Net [Member]
Summary Of Basis Of Presentation And Significant Accounting Policies [Line Items]
Unrealized gain (loss)		$ (58,861)	$ 29,430
Minimum [Member]
Summary Of Basis Of Presentation And Significant Accounting Policies [Line Items]
Minimum amortization period of compensation cost on straight line basis		1 year
Maximum [Member]
Summary Of Basis Of Presentation And Significant Accounting Policies [Line Items]
Minimum amortization period of compensation cost on straight line basis		3 years

XML 37 R26.htm IDEA: XBRL DOCUMENT

Basis of Presentation and Significant Accounting Policies - Fair Value Measurement Specific to Assets or Liability (Detail) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Short-Term Bond Fund [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments Fair Value Disclosure	$ 26,496,992	$ 26,516,711
U.S. Treasuries [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments Fair Value Disclosure	31,845,586
Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market funds	19,343,497	56,820,688
Quoted Prices in Active Markets for Identical Assets/Liabilities (Level 1) [Member] \| Short-Term Bond Fund [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments Fair Value Disclosure	26,496,992	26,516,711
Quoted Prices in Active Markets for Identical Assets/Liabilities (Level 1) [Member] \| Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market funds	19,343,497	$ 56,820,688
Significant Other Observable Inputs (Level 2) [Member] \| U.S. Treasuries [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments Fair Value Disclosure	$ 31,845,586

- Definition

Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.

+ References + Details

XML 38 R27.htm IDEA: XBRL DOCUMENT

Basis of Presentation and Significant Accounting Policies - Stock-Based Compensation Expense (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	$ 971,340	$ 754,144
Research and Development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	294,315	206,352
General and Administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	$ 677,025	$ 547,792

XML 39 R28.htm IDEA: XBRL DOCUMENT

Basis of Presentation and Significant Accounting Policies - Potential Shares Excluded from Determination of Basic and Diluted Net Loss Per Share (Detail) - shares	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential equivalent common stock excluded	6,902,500	8,522,663
Options to Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential equivalent common stock excluded	6,902,500	6,088,333
Warrants Liability, at Fair Value [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential equivalent common stock excluded		2,407,663
Unvested Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential equivalent common stock excluded		26,667

XML 40 R29.htm IDEA: XBRL DOCUMENT

Warrants Liability, at Fair Value - Additional Information (Detail) - USD ($)	1 Months Ended	3 Months Ended
	Oct. 31, 2011	Mar. 31, 2018	Mar. 31, 2017
Class of Warrant or Right [Line Items]
Recognition of warrants fair value at date of issuance			$ 0
October 28, 2011 Warrants [Member] \| Warrants Liability, at Fair Value [Member]
Class of Warrant or Right [Line Items]
Recognition of warrants fair value at date of issuance	$ 1,300,000
Warrants expiration date		May 02, 2017
Number of warrants exercised during the period			0

XML 41 R30.htm IDEA: XBRL DOCUMENT

Warrants Liability, at Fair Value - Summary of Assumptions Used in Black-Scholes Model to Calculate Fair Value of Warrants Liability (Detail) - Warrants Liability, at Fair Value [Member]	3 Months Ended
	Mar. 31, 2017
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Risk free interest rate	1.03%
Expected term	1 month 2 days
Expected volatility	110.00%
Expected dividend yield	0.00%
Expected forfeiture rate	0.00%

XML 42 R31.htm IDEA: XBRL DOCUMENT

Warrants Liability, at Fair Value - Summary of Company's Warrants Liability Activity (Detail)	3 Months Ended
	Mar. 31, 2017 USD ($)
Fair Value Disclosures [Abstract]
Fair value, beginning of period	$ 122,226
Issuance of warrants	0
Exercise of warrants	0
Change in fair value	397,235
Fair value, end of period	$ 519,461

XML 43 R32.htm IDEA: XBRL DOCUMENT

Short Term Investment - Summary of Short Term Investment by Security Type (Detail) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2018	Dec. 31, 2017
Net Investment Income [Line Items]
Amortized cost	$ 58,423,265
Gross Unrealized Losses	(80,687)
Estimated Fair Value	58,342,578
Short-Term Bond Fund [Member]
Net Investment Income [Line Items]
Amortized cost	26,555,853	$ 26,487,281
Gross Unrealized Gains		29,430
Gross Unrealized Losses	(58,861)
Estimated Fair Value	26,496,992	$ 26,516,711
U.S. Treasuries [Member]
Net Investment Income [Line Items]
Amortized cost	31,867,412
Gross Unrealized Losses	(21,826)
Estimated Fair Value	$ 31,845,586

XML 44 R33.htm IDEA: XBRL DOCUMENT

Short Term Investments - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Investments, Debt and Equity Securities [Abstract]
Realized gain losses from available for sale securities	$ 0	$ 0

XML 45 R34.htm IDEA: XBRL DOCUMENT

Prepaid Expenses and Other Current Assets - Prepaid Expenses and Other Current Assets (Detail) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid research fees	$ 249,094	$ 388,977
Prepaid insurance	501,181	638,139
Prepaid pre-commercialization fees	76,900	65,000
Prepaid subscription fees	92,916	23,347
Prepaid rent	20,981
Other	51,756	58,281
Total prepaid expenses and other current assets	$ 992,828	$ 1,173,744

XML 46 R35.htm IDEA: XBRL DOCUMENT

Property and Equipment, net - Property and Equipment, net (Detail) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 350,554	$ 350,554
Less: Accumulated depreciation	(167,184)	(159,169)
Total property and equipment, net	183,370	191,385
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	27,915	27,915
Furniture and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	169,931	169,931
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 152,708	$ 152,708

XML 47 R36.htm IDEA: XBRL DOCUMENT

Property and Equipment, net - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Property, Plant and Equipment [Abstract]
Depreciation expenses	$ 8,015	$ 12,958

XML 48 R37.htm IDEA: XBRL DOCUMENT

Accrued Expenses and Other Liabilities - Schedule of Accrued Expenses and Other Liabilities (Detail) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Payables and Accruals [Abstract]
Accrued preclinical and clinical trial expenses	$ 990,080	$ 970,649
Accrued professional fees	558,260	227,457
Accrued compensation and benefits	54,548	821,935
Accrued license fees	278,750	252,500
Deferred rent and lease incentive	25,597	24,011
Other	19,136	24,035
Current accrued expenses and other liabilities	1,926,371	2,320,587
Deferred rent and lease incentive - non-current	150,395	157,456
Non-current accrued expenses and other liabilities	150,395	157,456
Total accrued expenses and other liabilities	$ 2,076,766	$ 2,478,043

XML 49 R38.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2018	Dec. 31, 2017
Commitments [Line Items]
Accrued license fees	$ 278,750	$ 252,500
Northwestern License Agreement [Member]
Commitments [Line Items]
License fee paid	424,885
Accrued license fees	278,750
Future milestone payment	$ 300,000
License Agreement with BioMarin [Member]
Commitments [Line Items]
Date on which strategic collaboration is entered into	Oct. 26, 2012
Royalty agreement period	7 years
Net sales royalty threshold	$ 100,000,000
Milestone payment due upon NDA acceptance	2,600,000
Milestone payment due upon NDA approval	$ 7,200,000
Milestone Payment Description	However, under BioMarin’s agreement with the former Huxley stockholders (and under the Company’s license agreement with BioMarin), BioMarin’s obligation to pay the milestone payments due to the former Huxley stockholders (and the Company’s corresponding obligation to pay such milestone payments) expired because the milestones were not satisfied by April 20, 2018.
Costs paid for Firdapse joint studies	$ 3,800,000
License Agreement with BioMarin [Member] \| Minimum [Member]
Commitments [Line Items]
Percentage of royalty on net sales	7.00%
License Agreement with BioMarin [Member] \| Maximum [Member]
Commitments [Line Items]
Percentage of royalty on net sales	10.00%
License Agreement with BioMarin [Member] \| Third Party Licensor [Member] \| Lems or Cms [Member]
Commitments [Line Items]
Milestone payment due upon new drug application acceptance	$ 150,000
License Agreement with BioMarin [Member] \| Third Party Licensor [Member] \| Lems [Member]
Commitments [Line Items]
Milestone payment due upon new drug application approval	3,000,000
License Agreement with BioMarin [Member] \| Huxley [Member] \| Lems or Cms [Member]
Commitments [Line Items]
Milestone payment due upon new drug application acceptance	2,425,000
License Agreement with BioMarin [Member] \| Huxley [Member] \| Lems [Member]
Commitments [Line Items]
Milestone payment due upon new drug application approval	$ 4,200,000

XML 50 R39.htm IDEA: XBRL DOCUMENT

Income Taxes - Additional Information (Detail)	3 Months Ended	12 Months Ended
Income Taxes - Additional Information (Detail)	Mar. 31, 2018	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Valuation allowance	100.00%	100.00%

XML 51 R40.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (2016 Shelf Registration Statement) - Additional Information (Detail)	Dec. 23, 2016 USD ($)
2016 Shelf Registration Statement [Member]
Stockholders' Equity [Line Items]
Maximum dollar amount of common stock to be issued under shelf registration statement	$ 33,800,000

XML 52 R41.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (2017 Shelf Registration Statement) - Additional Information (Detail) - USD ($)		3 Months Ended
	Nov. 28, 2017	Mar. 31, 2018	Jul. 12, 2017
Underwritten Public Offering [Member]
Stockholders' Equity [Line Items]
Number of common stock sold in offering	16,428,572
Common stock issued, price per share	$ 3.50
Gross proceeds from issuance of common stock	$ 57,500,000
Offering expenses	$ 3,700,000
2017 Shelf Registration Statement [Member]
Stockholders' Equity [Line Items]
Maximum dollar amount of securities to be issued under shelf registration statement			$ 150,000,000
Value of common stock available for future sale		$ 92,500,000

XML 53 R42.htm IDEA: XBRL DOCUMENT

Stock Compensation - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Proceeds from exercise of stock options	$ 33,032
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation	$ 0	$ 18,608
Restricted stock unit granted	0	0
Options to Purchase Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option granted, contractual term	7 years	7 years
Stock options granted	1,772,500	1,520,000
Stock-based compensation	$ 971,340	$ 735,536
Stock option vested during the period	744,998	255,000
Number of stock options exercised	36,666	0
Proceeds from exercise of stock options	$ 33,032
Unrecognized compensation expense related to non-vested stock compensation awards granted under the Plan	$ 4,810,000
Expected remaining weighted average vesting period	2 years 4 months 2 days
Options to Purchase Common Stock [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting Period	1 year	1 year
Options to Purchase Common Stock [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting Period	3 years	3 years

EXCEL 54 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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end XML 55 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 56 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 58 FilingSummary.xml IDEA: XBRL DOCUMENT 3.8.0.1 html 79 175 1 false 33 0 false 4 false false R1.htm 101 - Document - Document and Entity Information Sheet http://www.catalystpharma.com/taxonomy/role/DocumentandEntityInformation Document and Entity Information Cover 1 false false R2.htm 103 - Statement - Consolidated Balance Sheets Sheet http://www.catalystpharma.com/taxonomy/role/StatementOfFinancialPositionClassified Consolidated Balance Sheets Statements 2 false false R3.htm 104 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.catalystpharma.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 105 - Statement - Consolidated Statements of Operations and Comprehensive Loss (unaudited) Sheet http://www.catalystpharma.com/taxonomy/role/StatementOfIncome Consolidated Statements of Operations and Comprehensive Loss (unaudited) Statements 4 false false R5.htm 106 - Statement - Consolidated Statement of Stockholders' Equity (unaudited) Sheet http://www.catalystpharma.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome Consolidated Statement of Stockholders' Equity (unaudited) Statements 5 false false R6.htm 107 - Statement - Consolidated Statements of Cash Flows (unaudited) Sheet http://www.catalystpharma.com/taxonomy/role/StatementOfCashFlowsIndirect Consolidated Statements of Cash Flows (unaudited) Statements 6 false false R7.htm 108 - Disclosure - Organization and Description of Business Sheet http://www.catalystpharma.com/taxonomy/role/NotesToFinancialStatementsNatureOfOperations Organization and Description of Business Notes 7 false false R8.htm 109 - Disclosure - Basis of Presentation and Significant Accounting Policies Sheet http://www.catalystpharma.com/taxonomy/role/NotesToFinancialStatementsBasisOfPresentationAndSignificantAccountingPoliciesTextBlock Basis of Presentation and Significant Accounting Policies Notes 8 false false R9.htm 110 - Disclosure - Warrants Liability, at Fair Value Sheet http://www.catalystpharma.com/taxonomy/role/NotesToFinancialStatementsWarrantsLiabilityAtFairValueTextBlock Warrants Liability, at Fair Value Notes 9 false false R10.htm 111 - Disclosure - Short-term Investments Sheet http://www.catalystpharma.com/taxonomy/role/NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock Short-term Investments Notes 10 false false R11.htm 112 - Disclosure - Prepaid Expenses and Other Current Assets Sheet http://www.catalystpharma.com/taxonomy/role/NotesToFinancialStatementsPrepaidExpensesAndOtherCurrentAssetsTextBlock Prepaid Expenses and Other Current Assets Notes 11 false false R12.htm 113 - Disclosure - Property and Equipment, net Sheet http://www.catalystpharma.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock Property and Equipment, net Notes 12 false false R13.htm 114 - Disclosure - Accrued Expenses and Other Liabilities Sheet http://www.catalystpharma.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock Accrued Expenses and Other Liabilities Notes 13 false false R14.htm 115 - Disclosure - Commitments and Contingencies Sheet http://www.catalystpharma.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock Commitments and Contingencies Notes 14 false false R15.htm 116 - Disclosure - Income Taxes Sheet http://www.catalystpharma.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock Income Taxes Notes 15 false false R16.htm 117 - Disclosure - Stockholders' Equity Sheet http://www.catalystpharma.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock Stockholders' Equity Notes 16 false false R17.htm 118 - Disclosure - Stock Compensation Sheet http://www.catalystpharma.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Stock Compensation Notes 17 false false R18.htm 119 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies) Sheet http://www.catalystpharma.com/taxonomy/role/NotesToFinancialStatementsBasisOfPresentationAndSignificantAccountingPoliciesTextBlockPolicies Basis of Presentation and Significant Accounting Policies (Policies) Policies http://www.catalystpharma.com/taxonomy/role/NotesToFinancialStatementsBasisOfPresentationAndSignificantAccountingPoliciesTextBlock 18 false false R19.htm 120 - Disclosure - Basis of Presentation and Significant Accounting Policies (Tables) Sheet http://www.catalystpharma.com/taxonomy/role/NotesToFinancialStatementsBasisOfPresentationAndSignificantAccountingPoliciesTextBlockTables Basis of Presentation and Significant Accounting Policies (Tables) Tables http://www.catalystpharma.com/taxonomy/role/NotesToFinancialStatementsBasisOfPresentationAndSignificantAccountingPoliciesTextBlock 19 false false R20.htm 121 - Disclosure - Warrants Liability, at Fair Value (Tables) Sheet http://www.catalystpharma.com/taxonomy/role/NotesToFinancialStatementsWarrantsLiabilityAtFairValueTextBlockTables Warrants Liability, at Fair Value (Tables) Tables http://www.catalystpharma.com/taxonomy/role/NotesToFinancialStatementsWarrantsLiabilityAtFairValueTextBlock 20 false false R21.htm 122 - Disclosure - Short-term Investments (Tables) Sheet http://www.catalystpharma.com/taxonomy/role/NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlockTables Short-term Investments (Tables) Tables http://www.catalystpharma.com/taxonomy/role/NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock 21 false false R22.htm 123 - Disclosure - Prepaid Expenses and Other Current Assets (Tables) Sheet http://www.catalystpharma.com/taxonomy/role/NotesToFinancialStatementsPrepaidExpensesAndOtherCurrentAssetsTextBlockTables Prepaid Expenses and Other Current Assets (Tables) Tables http://www.catalystpharma.com/taxonomy/role/NotesToFinancialStatementsPrepaidExpensesAndOtherCurrentAssetsTextBlock 22 false false R23.htm 124 - Disclosure - Property and Equipment, net (Tables) Sheet http://www.catalystpharma.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables Property and Equipment, net (Tables) Tables http://www.catalystpharma.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock 23 false false R24.htm 125 - Disclosure - Accrued Expenses and Other Liabilities (Tables) Sheet http://www.catalystpharma.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables Accrued Expenses and Other Liabilities (Tables) Tables http://www.catalystpharma.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock 24 false false R25.htm 126 - Disclosure - Basis of Presentation and Significant Accounting Policies - Additional Information (Detail) Sheet http://www.catalystpharma.com/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformation Basis of Presentation and Significant Accounting Policies - Additional Information (Detail) Details 25 false false R26.htm 127 - Disclosure - Basis of Presentation and Significant Accounting Policies - Fair Value Measurement Specific to Assets or Liability (Detail) Sheet http://www.catalystpharma.com/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesFairValueMeasurementSpecificToAssetsOrLiability Basis of Presentation and Significant Accounting Policies - Fair Value Measurement Specific to Assets or Liability (Detail) Details 26 false false R27.htm 128 - Disclosure - Basis of Presentation and Significant Accounting Policies - Stock-Based Compensation Expense (Detail) Sheet http://www.catalystpharma.com/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesStockBasedCompensationExpense Basis of Presentation and Significant Accounting Policies - Stock-Based Compensation Expense (Detail) Details 27 false false R28.htm 129 - Disclosure - Basis of Presentation and Significant Accounting Policies - Potential Shares Excluded from Determination of Basic and Diluted Net Loss Per Share (Detail) Sheet http://www.catalystpharma.com/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPotentialSharesExcludedFromDeterminationOfBasicAndDilutedNetLossPerShare Basis of Presentation and Significant Accounting Policies - Potential Shares Excluded from Determination of Basic and Diluted Net Loss Per Share (Detail) Details 28 false false R29.htm 130 - Disclosure - Warrants Liability, at Fair Value - Additional Information (Detail) Sheet http://www.catalystpharma.com/taxonomy/role/DisclosureWarrantsLiabilityAtFairValueAdditionalInformation Warrants Liability, at Fair Value - Additional Information (Detail) Details 29 false false R30.htm 131 - Disclosure - Warrants Liability, at Fair Value - Summary of Assumptions Used in Black-Scholes Model to Calculate Fair Value of Warrants Liability (Detail) Sheet http://www.catalystpharma.com/taxonomy/role/DisclosureWarrantsLiabilityAtFairValueSummaryOfAssumptionsUsedInBlackScholesModelToCalculateFairValueOfWarrantsLiability Warrants Liability, at Fair Value - Summary of Assumptions Used in Black-Scholes Model to Calculate Fair Value of Warrants Liability (Detail) Details 30 false false R31.htm 132 - Disclosure - Warrants Liability, at Fair Value - Summary of Company's Warrants Liability Activity (Detail) Sheet http://www.catalystpharma.com/taxonomy/role/DisclosureWarrantsLiabilityAtFairValueSummaryOfCompanysWarrantsLiabilityActivity Warrants Liability, at Fair Value - Summary of Company's Warrants Liability Activity (Detail) Details 31 false false R32.htm 133 - Disclosure - Short Term Investment - Summary of Short Term Investment by Security Type (Detail) Sheet http://www.catalystpharma.com/taxonomy/role/DisclosureShortTermInvestmentSummaryOfShortTermInvestmentBySecurityType Short Term Investment - Summary of Short Term Investment by Security Type (Detail) Details 32 false false R33.htm 134 - Disclosure - Short Term Investments - Additional Information (Detail) Sheet http://www.catalystpharma.com/taxonomy/role/DisclosureShortTermInvestmentsAdditionalInformation Short Term Investments - Additional Information (Detail) Details 33 false false R34.htm 135 - Disclosure - Prepaid Expenses and Other Current Assets - Prepaid Expenses and Other Current Assets (Detail) Sheet http://www.catalystpharma.com/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsPrepaidExpensesAndOtherCurrentAssets Prepaid Expenses and Other Current Assets - Prepaid Expenses and Other Current Assets (Detail) Details 34 false false R35.htm 136 - Disclosure - Property and Equipment, net - Property and Equipment, net (Detail) Sheet http://www.catalystpharma.com/taxonomy/role/DisclosurePropertyAndEquipmentNetPropertyAndEquipmentNet Property and Equipment, net - Property and Equipment, net (Detail) Details 35 false false R36.htm 137 - Disclosure - Property and Equipment, net - Additional Information (Detail) Sheet http://www.catalystpharma.com/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformation Property and Equipment, net - Additional Information (Detail) Details 36 false false R37.htm 138 - Disclosure - Accrued Expenses and Other Liabilities - Schedule of Accrued Expenses and Other Liabilities (Detail) Sheet http://www.catalystpharma.com/taxonomy/role/DisclosureAccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherLiabilities Accrued Expenses and Other Liabilities - Schedule of Accrued Expenses and Other Liabilities (Detail) Details 37 false false R38.htm 139 - Disclosure - Commitments and Contingencies - Additional Information (Detail) Sheet http://www.catalystpharma.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation Commitments and Contingencies - Additional Information (Detail) Details 38 false false R39.htm 140 - Disclosure - Income Taxes - Additional Information (Detail) Sheet http://www.catalystpharma.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation Income Taxes - Additional Information (Detail) Details 39 false false R40.htm 141 - Disclosure - Stockholders' Equity (2016 Shelf Registration Statement) - Additional Information (Detail) Sheet http://www.catalystpharma.com/taxonomy/role/DisclosureStockholdersEquity2016ShelfRegistrationStatementAdditionalInformation Stockholders' Equity (2016 Shelf Registration Statement) - Additional Information (Detail) Details http://www.catalystpharma.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock 40 false false R41.htm 142 - Disclosure - Stockholders' Equity (2017 Shelf Registration Statement) - Additional Information (Detail) Sheet http://www.catalystpharma.com/taxonomy/role/DisclosureStockholdersEquity2017ShelfRegistrationStatementAdditionalInformation Stockholders' Equity (2017 Shelf Registration Statement) - Additional Information (Detail) Details http://www.catalystpharma.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock 41 false false R42.htm 143 - Disclosure - Stock Compensation - Additional Information (Detail) Sheet http://www.catalystpharma.com/taxonomy/role/DisclosureStockCompensationAdditionalInformation Stock Compensation - Additional Information (Detail) Details 42 false false All Reports Book All Reports cprx-20180331.xml cprx-20180331.xsd cprx-20180331_cal.xml cprx-20180331_def.xml cprx-20180331_lab.xml cprx-20180331_pre.xml http://xbrl.sec.gov/invest/2013-01-31 http://xbrl.sec.gov/dei/2014-01-31 http://fasb.org/us-gaap/2017-01-31 true true ZIP 60 0001193125-18-157513-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-18-157513-xbrl.zip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౥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�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

Large accelerated filer

Accelerated Filer

Non-accelerated filer

☐ (Do not check if a smaller reporting company)

Smaller reporting company

Emerging growth company